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1. Introduction 
 
It’s a windy autumn night at Stockholm and Laura is just arriving home from Karen’s house (her best 
friend from school) and she just realized that there is no one home and she plans to take advantage of 
this by monopolising the TV and lying down on her favourite couch at her family room. 
 
While Laura is doing this her parents and her little sister Jasmine are still at the hospital with Dr. 
Spencer trying to figure out which preventive therapy would be the most suitable for Jasmines from a 
foreseen congenital disorder that would make her loose her sight in a couple of years. This disease was 
found when Jasmine DNA was studied and profiled at her birth enabling Dr. Spencer and the genetics 
department of the hospital to set an action course in order to enhance Jasmines quality of life. 
 
After two more hours and a couple of extra lab tests they decide to use some foetal stem cells, a 
revolutionary technique that has changed the way people live and overcome their illnesses and diseases.  
 
Dr. Spencer decides to begin with the stem cell therapy in a week. After two sessions of therapy and a 
couple of evaluation follow up appointments Jasmine is released and now she is out of any risk from this 
degenerative disease. 
 
As unreal, distant or taken out of a science fiction novel the previous story might sound this is the future of 
medicine in a couple of decades. Human stem cell research poses an unimaginable new horizon for human 
health, where prevention will be the key topic (especially with children) and gene replacement therapy and 
organs replacement surgeries will be the norm within developed countries.  
This is a very exciting and promising time to be living at since nowadays the foundations for that future 
development of this technology are taken place by the different biotechnology innovation systems of 
countries around the world. In order to ensure that this future snapshot will come truth several key elements 
must work together (society, companies and laws). Unfortunately Europe as a whole unity is running behind 
other countries mainly because of the lack of an appropriate community legislation that gives general access 
to all Member States to a safe and harmonised human stem cells patent system.  
So far the commission has managed not to answer the important question regarding the possibility to patent 
processes and products deriving from human stem cells in spite the fact that national laws from some 
Member States allow it, thus resulting on a disadvantageous position for most countries. 
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This later fact not only affects the MS human stem cell national innovation systems resulting in an inefficient 
allocation of resources which impact universities, employees, companies, researchers and ultimately the 
general public, but at the end of the day it affects the development of the European human stem cell 
innovation system position globally. It is imperative and of paramount consequences for European policy 
makers to give a position regarding this topic. 
 
a. Purpose 
 
The purpose of this paper is for the reader to realise how national innovation systems are deeply intertwined 
with the legal background of a country and to understand the processes that involves national innovation 
systems specifically regarding the stem cell / genetics research and how the need for specific community law 
must be considered targeting the stem cell patents. The legal part will try to answer: Why is it important 
given the actual state of the European stem cell national innovation systems for the European Commission to 
take a stand and tackle issues regarding the patenting of the human stem cell innovations? This is done from 
a country industry analysis (business approach) and then linking it with competition law from a community 
stand point of view (that tackles biotechnology issues). In order to achieve this the paper is divided into three 
separate analyses beginning with a theoretical background of general biotechnology / genetic terms that will 
enable the reader to have a general understanding of the importance of this kind or research ( genetics / stem 
cell research). The chosen countries case studies exemplify very diverse economies and development 
perspective from the traditionally R&D intensive to the least and from the biggest countries in Europe to one 
of the smallest, thus giving cultural, legal, economic and scientific variety. 
 
Following this part the core of the paper is presented by 4 case studies from different member states, this 
analysis is done from a national perspective encompassing firms, laws and financial resources; key factors 
that build up national innovation systems. The focus is to have a general mapping of where the selected 
member states position themselves regarding their stem cell innovation processes. 
Finally the third part of the paper are the community legal issues that this kind of intensive R&D industry 
finds across the community and why it is important to have a very specific answer from the commission 
regarding stem cell practices since the community is lacking of general guidelines that allow all member 
states to have the same level of legal competitiveness. 
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b. Method 
 
Since this thesis deals with social, industrial and legal issues it was only logical to begin by setting a general 
but strong theoretical foundation about the relevance of stem cell research in order to provide with a general 
understanding about why and how stem cell research is answering common questions giving clarification for 
the following parts that deal with the national innovation in stem cell research of 4 selected countries (case 
studies) and finally the legal part that concludes with the disparities of the laws (national and community 
wise) regarding human stem cells and biotechnology. 
Most of the information used are primary sources (specially for the legal part) and secondary sources as well 
thought the paper.  
1. Choice of literature 
 
The 25 recommendations from the commission (2004) were the detonator for this thesis since they tackle 
with very important (ethical and human rights) points. Further more, socio-legal and comparative law 
literature were used extensible in order to achieve a sensible and sensitive approach that enabled the rest of 
the thesis to be supported. EC legislation, commission decisions, case law, journals and devoted scientific 
magazines have also been part of the literature used for this academic paper. 
 
The choice of literature is an array of official sources such as national institutions of science of several 
Member States; community law compiled by: Commissions recommendations, Directives, Treaties and Case 
Law; scientific and some legal journals in order to have opinions different opinions and points of view of 
experts. Most of the sources consulted were online sources via online journals, online databases or directly 
through the institution website (taking advantage of the ELIN system provided by the Lund University 
Libraries) 
 
The chosen countries to be studied have very different approaches and policies towards stem cell research 
and national innovation processes and show the socio-legal approach of different European member states to 
stem cell research and the link to their national innovation processes. It is also important to emphasise the 
heterogeneity of the countries economies beginning with the United Kingdom as a large country with high 
income, Germany which has been the financial engine of the Union and is as well a large country with high 
income, Spain with a less developed R&D industry but also a large country and economy but with a very 
different approach since it’s a Latin European state, and last comes The Netherlands as an example of a small 
country with high income. 
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c. Delimitations 
 
The focus of the thesis as mentioned previously is the comparison of biotech / stem cell innovation system 
from selected European countries and the necessity for the commission to answer crucial questions that have 
been avoided in the past and to have a harmonised community law that clearly approaches stem cell research 
issues in a very clear and precise way. 
 
Evidently the impact of the national innovation systems and the legal structure of a country influences the 
base that enables the further development of the R&D structure (links between policy makers, legal systems, 
governmental agencies, universities, private firms and ultimately with the market). This paper will not take 
into consideration any other countries outside the EU for clarity and time reasons or any religious factor but 
only the ethical arguments of the commission and the European Court of Human Rights. 
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2. Scientific Background  
a. Stem cells, a definition:  
 
Stem cells are cells that can divide to produce either cells like themselves (self-renewal), or of one or several 
specific differentiated types. Stem cells are not yet fully differentiated and therefore can reconstitute one or 
several types of tissues.1
 
“Stem cells have the remarkable potential to develop into many different cell types in the body. Serving as a 
sort of repair system for the body, they can theoretically divide without limit to replenish other cells as long 
as the person or animal is still alive. When a stem cell divides, each new cell has the potential to either 
remain a stem cell or become another type of cell with a more specialized function, such as a muscle cell, a 
red blood cell, or a brain cell”.2
b. Types of Stem Cells:  
 
According to the Report On Human Embryonic Stem Cell Research “Different kinds of stem cells can be 
distinguished according to their potential to differentiate. They are progenitor, multipotent or pluripotent 
stem cells.  
 
• Progenitor Stem Cells are those whose terminally differentiated progeny consist of a single cell type only. 
For instance, epidermal stem cells or spermatogonial3  stem cells can differentiate respectively into only 
keratinocyte4 and spermatozoa.  
• Multipotent Stem Cells are those which can give rise to several terminally differentiated cell types 
constituting a specific tissue or organ. Examples are skin stem cells which give rise to epidermal cells, 
sebaceous glands and hair follicles or haematopoietic stem cells, which give rise to all the diverse blood cells 
(erythrocytes, lymphocytes, antibody-producing cells and so on), and neural stem cells, which give rise to all 
 
1 McLaren Anne, Hermerén Göran. Ethical Aspects of Human Stem Cell Research and Use 14 Nov. 2000, Pg 3 Opinion of the 
European Group on Ethics In Science and New Technologies to the European Commission  
2 The Official National Institute of Health Resource for Stem Cell Research. 2005, Maryland USA  
http://stemcells.nih.gov/staticresources/info/basics/StemCellBasics.pdf  
3 Any of the cells of the gonads in male organisms that are the progenitors of spermatocytes. Also called spermatoblast. (The 
American Heritage® Stedman's Medical Dictionary 2002 by Houghton Mifflin Company.)  
4 An epidermal cell that produces keratin. (The American Heritage® Stedman's Medical Dictionary 2002 by Houghton Mifflin 
Company.)  
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the cell types in the nervous system, including glia (sheath cells), and the many different types of neurons. 
(Both multipotent and progenitor stem cells may persist through life allowing the foetus to form tissue and 
organs and in the adult to replenish tissue whose cells have a limited life span like skin, intestinal and 
haematopoietic stem cells. Without these cells in our body we would dye due to lack of tissue regeneration).  
 
• Pluripotent Stem Cells are able to give rise to all different cell types in vitro Nevertheless, they cannot on 
their own form an embryo. Pluripotent stem cells, which are isolated from primordial germ cells in the foetus, 
are called: embryonic germ cells ("EG cells"). Those stem cells, which are isolated from the inner cell mass 
of a blastocyst5 -stage embryo, are called: embryonic stem cells ("ES cells”).” (These kind of cells do not 
occur naturally in the body, which distinguishes them from the two previous ones)6
Please refer to annexe “a” for further understanding about the differentiation process.  
c. Where can stem cells be found?  
 
“Scientists primarily work with three kinds of stem cells from humans: embryonic stem cells, foetal origin 
stem cells and adult stem cells. The first kinds of stem cells are derived from embryos that develop from eggs 
that have been fertilized in vitro and then donated for research purposes with informed consent of the donors. 
They are not derived from eggs fertilized in a woman's body. The embryos from which human embryonic 
stem cells are derived are typically four or five days old and are a hollow microscopic ball of cells called the 
blastocyst.  
Stem cells of foetal origin can be retrieved from the umbilical cord blood (haematopoietic stem cells) and the 
adult stem cells. Finally adult stem cells have been identified in many organs and tissues. One important 
point to understand about adult stem cells is that there are a very small number of stem cells in each tissue. 
The adult tissues reported to contain stem cells include brain, bone marrow, peripheral blood, blood vessels, 
skeletal muscle, skin and liver.” 7
d. Importance of stem cell research:  
 
 
5 The modified blastula stage of mammalian embryos, consisting of the inner cell mass and a thin trophoblast layer enclosing the 
blastocoel. Also called blastodermic vesicle. (The American Heritage® Stedman's Medical Dictionary 2002 by Houghton Mifflin 
Company.)  
6 McLaren Anne, Hermerén Göran. Ethical Aspects of Human Stem Cell Research and Use 14 Nov. 2000, Pg 3 Opinion of the 
European Group on Ethics In Science and New Technologies to the European Commission  
7 McLaren Anne, Hermerén Göran. Ethical Aspects of Human Stem Cell Research and Use 14 Nov. 2000, Pg 3 Opinion of the 
European Group on Ethics In Science and New Technologies to the European Commission  
The Official National Institute of Health Resource for Stem Cell Research. 2005, Maryland USA  
http://stemcells.nih.gov/staticresources/info/basics/StemCellBasics.pdf  
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“Embryonic stem cells are of great interest to medicine and science because of their ability to develop into 
virtually any other cell made by the human body. In theory, if stem cells can be grown and their development 
directed in culture, it would be possible to grow cells of medical importance such as bone marrow, neural 
tissue or muscle. 
 
The first potential applications of human embryonic stem cell technology may be in the area of drug 
discovery. The ability to grow pure populations of specific cell types offers a proving ground for chemical 
compounds that may have medical importance. Treating specific cell types with chemicals and measuring 
their response offers a short-cut to sort out chemicals that can be used to treat the diseases that involve those 
specific cell types. Stem cell technology, therefore, would permit the rapid screening of hundreds of 
thousands of chemicals that must now be tested through much more time-consuming processes.”8
 
Some examples of potential treatment include diseases like juvenile onset diabetes mellitus and Parkinson's 
disease (replacing the dopamine-producing cells in the brains of Parkinson's patients) occurs because of 
defects in one of just a few cells types. “Replacing faulty cells with healthy ones offers hope of lifelong 
treatment. Similarly, failing hearts and other organs, in theory, could be shored up by injecting healthy cells 
to replace damaged or diseased cells.9  As mention previously stem cells therapy will literally change the way 
we live and heal since no more conventional drugs will be necessary (why to cure when you can get a brand 
new organ?) not only our lives will be changed but the whole traditional pharmaceutical industry would be 
forced to shift.  
 
8 The Biotech Journal 2004,What's So Great About Embryonic Stem Cells? 
 http://www.biotechjournal.com/Journal/July2004/embryonicstemcells.pdf 
9 McLaren Anne, Hermerén Göran. Ethical Aspects of Human Stem Cell Research and Use 14 Nov. 2000, Pg 3 Opinion of the 
European Group on Ethics In Science and New Technologies to the European Commission  
The Official National Institute of Health Resource for Stem Cell Research. 2005, Maryland USA  
http://stemcells.nih.gov/staticresources/info/basics/StemCellBasics.pdf  
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3. National Innovation Systems 
 
a. Definition 
The OECD defines the national innovation systems as the “flows of technology and information among 
people, enterprises and institutions which are key to the innovative process. Innovation and technology 
development are the result of a complex set of relationships among actors in the system, which includes 
enterprises, universities and government research institutes. For policy-makers, an understanding of the 
national innovation system can help identify leverage points for enhancing innovative performance and 
overall competitiveness. It can assist in pinpointing mismatches within the system, both among institutions 
and in relation to government policies, which can thwart technology development and innovation. Policies 
which seek to improve networking among the actors and institutions in the system and which aim at 
enhancing the innovative capacity of firms, particularly their ability to identify and absorb technologies, are 
most valuable in this context.”10
 
In the national innovation system approach, “innovative activity is usually analyzed in a broader sense 
instead of focusing solely on the number of introduced product and process innovations in a country, it 
encompasses also research and development efforts by business firms and public actors as well as the 
determinants of innovation like, for instance, learning processes, incentive mechanisms or the availability of 
skilled labour.”11  
 
In order to understand a national innovation system it is paramount to understand how technical advance 
occurs in the modern world, and they key processes and institutions involved such as R&D facilities, 
scientists and engineers trained by universities and attached to business firms, universities, government 
agencies and policy makers; are the principle vehicles through which technological advance proceeds. Figure 
a (below) summarizes how the flow of these core knowledge factors studied in this paper: 
 
Figure a: Core knowledge flows in national innovation systems 
Type of Knowledge flow 
 
Main Indicator 
 
                                                 
10 Organisation for Economic Co-Operation and Development. 1997 National Innovation Systems 
http://www.oecd.org/dataoecd/35/56/2101733.pdf 
11 Markus Balzat & Horst Hanusch, 2003. Recent Trends in the Research on National Innovation Systems, Volkswirtschaftliche 
Diskussionsreihe 254, Universität Augsburg, Institut für Volkswirtschaftliche 
http://www.wiwi.uni-augsburg.de/vwl/institut/paper/254.pdf   
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Industry alliances                                              
 
Industry/university interactions 
Co-operative industry/University R&D 
Industry/University financing 
This will be assumed by the interaction 
between universities or research centres 
and by spin-off companies (mainly in the 
UK) 
 
Industry/research institute interactions 
 
Co-operative industry/Institute R&D 
Industry/Institute financing 
 
This indicator is mildly taken into account 
specially in Germany and The Netherlands  
 
b. Background 
 
As Nelson 1993 mentions a National Innovation System is a system that supports the ability/capacity of a 
country to innovate – especially to adapt and create science and technologies for economic and societal use. 
There is a clear sense of national technology that might be called “technonationalism”12 which is a mix of the 
different technological abilities of the companies of a specific country, but certainly this is not the only factor 
to take into consideration when talking about national innovation systems: 
“People: Linking and enabling knowledge, education, training, entrepreneurship. (The following chart 
explains how based within a need from human capacity the NIS build up from basic operators all the way to 
develop a R&D process.  
 As the following chart explains in a very simple but graphical way how education and training are a 
key element for the build up of NIS from a human perspective. The more labour intensive a job is the more 
less-qualified workers are needed and as soon as workers are trained and educated they develop technical 
skills which allow them to continue up the NIS ladder; furthermore, if more formal education is given within 
the appropriate environment engineering skills will be developed and finally the last step is to achieve a 
scientific R&D approach which requires the best trained and educated free-minded people. As noted the 
closer to the R&D processes the less people are required. 
                                                 
12 Nelson R. Richard , 1993. National Innovation Systems. Oxford Univesity Press New York 
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Policy environment: Focusing in under-funded areas, promoting new business opportunities, linking 
universities with the private sector, improving policies  
Infrastructure: Take advantage of existing networks with institutions, research centres and universities, 
finances and funding. 
Institutions: This push and pull process that institutions must do where the government is an important 
catalyst. 
Political will: This is one of the most important factors and key elements that lobbyist must push forward 
since without political will from politicians and law makers the whole process could be stalled.  
 
The following is a typical example of how a NIS works and is created from 3 different perspectives 
(depending on the development stage that the country is situated). The process is quite comprehensive and 
self explanatory where it begins by the acquisition of proven systems by imitation and then escalates to the 
assimilation of these innovation or discoveries, then it goes further to improve the previously imitated and 
assimilated innovation and finally in the most develop state it creates new knowledge, processes and products 
within such innovation system. 
 15 
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4. European Biotechnology Innovation System 
 
“Innovative performance is both a measure and a key component in national competitiveness and economic 
performance. In general, competitiveness can relate to three areas: currently produced goods and services; 
productivity in commercial flows; and competitive potential. “Sustained competitiveness depends upon the 
continual development of new and improved products, processes and services, and the transfer of know-how 
and technology between and within the actors of the “national system of innovation”. Such ‘technology 
transfer’ involves the flow of expertise or technology from one place and its application elsewhere, in a two-
way, ongoing activity which may cover management techniques and “best practice” as well as hardware, 
processes and materials.”14 
 
The European Biotechnology Innovation System is certainly influenced by several factors such as national al 
community legislation, different sectors that have a great influence for both local and supranational biotech 
European policy. 
As it will be shown these studies portray a very different reality regarding the national innovations systems 
between the chosen countries. In order to better understand the differences between different member states 
regarding their approach towards biotechnology and their innovation processes studies from several countries 
                                                 
13 Calestous Juma & Lee Yee-Cheong, 2005 “Innovation: applying knowledge in development,” UN Millennium Project, Task 
Force on Science, Technology, and Innovation  
14 British Council 2002. Innovation and Technology Transfer http://www.britishcouncil.org/science-publications-briefing-
sheets.htm  
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(United Kingdom, Spain, Germany and The Netherlands) were taken as a way of comparing them and gain a 
further view in this very specific sector. 
a. United Kingdom Biotech Innovation System 
1. Biotechnology policy background  
 
In the beginning of the 1980s the British government began having some emphasis on the biotechnology 
development of the country by the Spinks Report focusing in two important branches which were the 
developing of the scientific base and the commercial exploitation of the inventions. Later on the most 
targeted efforts were developed by the Biotechnology Directorate, which was established by the Science and 
Engineering Research Council in 1982. The Biotechnology Directorate, which was responsible for funding 
postgraduate students and academic research, was successful in its aims to foster a programme of strategic 
university research in biotechnology and to forge links between that research and industry. 
Rectifying  
2. Funding 
 
Funding in the UK comes from three main sources for providing government funds to public sector research. 
Under the so-called "dual support system" for funding university research, the Department for Education and 
Employment (or relevant Departments in Scotland, Wales and Northern Ireland) pay for the basic 
infrastructure for carrying out research. This money is distributed by the Higher Education Funding Councils. 
The second source is The Office of Science and Technology, within the Department of Trade and Industry 
(DTI), which provides funds for research projects and this money is allocated by Research Councils to their 
own Institutes and to university researchers. The OST also funds the Royal Society and Royal Academy of 
Engineering. The third source of funds is individual government departments which commission or carry out 
research to support specific policy objectives. (see figure 1) 
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Figure 1: Research funding in the UK 
15
To be more specific figure 2 shows in which way funding is being allocated to the biotechnology research 
not only from government sources but from charitable organisations. 
Figure 2: Biotechnology research funding 
16
                                                 
15 Senker Jacqueline, Brady Max and van Zwanenberg Paddy,  2000. European Biotechnology Innovation System UK Report, 
SPRU, University of Sussex, Brighton. http://www.sussex.ac.uk/spru/documents/uk.pdf 
16 Senker Jacqueline, Brady Max and van Zwanenberg Paddy,  2000. European Biotechnology Innovation System UK Report, 
SPRU, University of Sussex, Brighton. http://www.sussex.ac.uk/spru/documents/uk.pdf 
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There are several programmes and institutions that support the commercialisation of biotechnology such as: 
 (Department of Trade Industry): 
• The Biotechnology Mentoring and Incubator (BMI): providing protection and guidance to new 
biotech firms 
• Biotechnology Exploitation Platform (BEP): This programme aims to improve the administration of 
intellectual property issues. 
•  Manufacturing for Biotechnology: aims to find the production and research facilities to produce 
biotech products. It helps firms to find third parties (outsourcing) to streamline the production 
process 
• Biotechnology Industry Government Regulatory Advisory Group: helps firms to have a forum for 
them to exchange information and to asses the regulatory framework. 
3. Biotech Regulations 
 
The United Kingdom is one of the countries (as long with China, Japan, Sweden and Belgium) with a 
permissive policy on embryonic stem cell research meaning that various embryonic stem cell derivation 
techniques could be developed including somatic cell nuclear transfer (SCNT), also called research or 
therapeutic cloning17. These countries represent a global population of approximately 2.7 billion people. (See 
map on Annexe b. Map of Countries with permissive policy of embryonic stem cell research) 
 
The United Kingdoms’ regulatory and advisory system in biotechnology is the one in charge of approving 
products and to propose the legal framework in which these processes or products must be conducted.  There 
are several committees that tackled with different kind of deals and issues but nevertheless most of them 
focus with food and agriculture and medical issues that come up from the biotechnology spectrum.  On the 
other hand there is the Health and Safety Commission and the Health and Safety Executive (HSE) which are 
engaged in a more bureaucratic role since they deal with issues related to the safety of workers working in 
the biotech industry. At the same time the HSE follows the control of the regulations about the use of GMO 
(genetically modified organisms). 
Regulations controlling the contained used of genetically modified organisms, which have existed since 
1978, are administered by the HSE. The Advisory Committee on Genetic Modification (AGCM) provides the 
HSE with detailed notes on good practice for complying with these regulations.  (1 Senker et al 2000) 
 
 
17 SCNT is the transfer of a cell nucleus from a somatic or body cell into an egg from which the nucleus has been removed 
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Most of the national regulations and legislations regarding biotechnology come from The United Kingdom 
Parliament (House of the Lords) from the Stem Cell Committee as in the following legislations: Medicines 
Act 1968 and Medicines for Human Use Regulations 1994, Health Services circular HSC1998/126 (Clinical 
Procedures involving Xenotransplantation 18 ) under NHS Act 1977 and NHS and Community Care Act 
1990. 19  One of the most comprehensive documents regarding UK Stem Cell legislation is the 
Stem Cell Research – Report20 which represents the most effort to clarify all Human Stem Cell national 
issues. 
Regarding the patenting laws it is important to mention that the UK makes available by international laws 
patents of intellectual property based on the European Patent Convention (EPC 1978), The EU Directive on 
the Legal Protection of Biotechnological Inventions (98/44/EC) and the national patent system governed by 
the Patents Act 1977. 
4. Industry: 
 
According to the Association of the British Pharmaceutical Industry the British pharmaceutical sector is one 
of the strongest sectors in the country since they have ad a surplus in its trade with the rest of the world.  
 
The UK Biotechnology Handbook21  indicates that there are more than 97 biotech firms in the country 
involved with bio-pharmaceuticals (small and medium sized) (see Figure 3). “A significant number of 
companies have products on the market (41%) and even more offer contract research and other service 
activities (57%). Some indication of the market orientation of these companies may be gained from looking 
at where they conduct clinical trials and secure patents. The majority of clinical trials (both those conducted 
alone and those with partners) take place in the UK (49%); there are equal proportions of trials conducted 
with US and European partners (24% of each). The highest number of patents are national, but the other 
patenting activities of companies demonstrate their global interests. In terms of seeking scientific knowledge, 
these companies rely to a great extent on collaborations with national public sector research (64%). In their 
technological collaborations with other companies, however, US companies predominate (42% of 
 
18 Process of transplanting cells, tissues or organs from one species to another like from pigs to humans. 
19 Only relevant to Human Genetics. 
20 http://www.parliament.the-stationery-office.co.uk/pa/ld200102/ldselect/ldstem/83/8301.htm 
21 Crafts-Lightly Anita & Williams Ruth, 1999. The UK Biotechnology Handbook 98/99. Westward Digital Print, Cheltenham, 
UK.
 http://www.lub.lu.se/cgi-
bin/ipchk/http://elin.lub.lu.se/link2elin?genre=article&issn=0923179x&year=1999&volume=8&issue=6&collection=ejor&pages=
338-338&resid=beb46348c167517e7d329de247441565&lang=en
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partnerships). The main source of both product and technology licences for these firms is the UK; but the US 
is the second most important source.”22
a. Top stem cells firms in the UK 
 
There are 11 specialised stem cells firms in the country; most of them maintain a close link with universities 
or other sort of research facilities. Some firms generate revenues by using their licences in stem cell 
processes in order to be sustainable and to finance new kind of cell therapies that normally take several years 
(long term). Following, a chart23 is presented with more detailed information from these mentioned stem cell 
dedicated firms. 
Firm Description Finances 
Axordia Stem cell technologies for 
discovery therapy. Spin-off 
University of Sheffield 
Private firm funded by the 
University of Sheffield 
CellCentric Commercial exploitation of 
epigenetics and mechanisms 
that control cell functionality 
and fate. Spin-off university of 
Cambridge 
Private firm funded by the 
Rainbow Seed fund 
EpiStem Specialises in epithelial tissue 
and stem cell analysis. Spin-off 
the Paterson Institute for Cancer 
Research in Manchester 
Private firm and claims to 
produce profits. 
Intercytex Develops cell therapy products 
for wound care and aesthetic 
medicine 
Private firm raised money by 
equity funds 
Novathera To develop the ability to deliver 
mature differentiated stem cells 
using bioactive material 
constructs and the manipulation 
of bioactive materials. Spin-off 
Imperial College 
Private firm 
Odontis Tissue engineering of teeth 
based on the discovery that 
tooth development can be 
initiated by stem cells. Aims to 
create a biotooth. Spin-off 
Guy’s Hospital London 
Private firm funded by the 
Wellcome Trust  University 
Translation Award 
RegenTec Develops cell delivery. Spin-off 
the University of Nottingham 
Private firm funded by the 
University of Nottingham.  
                                                 
22 Senker Jacqueline, Brady Max and van Zwanenberg Paddy,  2000. European Biotechnology Innovation System UK Report, 
SPRU, University of Sussex, Brighton. http://www.sussex.ac.uk/spru/documents/uk.pdf  
23 Perrin Nicola, 2005. The Global Commercialisation of UK Stem Cell Research. UK Trade and Investment. 
http://www.fco.gov.uk/Files/kfile/UKTIStemCellsReportAugust2005,0.pdf  
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Reinnervate Research with neural stem cells. 
Spin-off the University of 
Durham. 
Private firm funded by grants 
from the University of Durham. 
Reneuron Develop cell transplantation 
treatments using human somatic 
stem cells for 
neurodegenerative diseases. 
Spin-off Institute of Psychiatry 
London 
Private firm and funded by 
Merlin Bioscience.  
Renovo Develop drugs to prevent 
scarring and fibrosis by 
promoting molecular 
mechanisms of tissue repair. 
Spin-off the University of 
Manchester 
Private firm and funded by 
different organisations 
StemCellSciences Creates technologies to grow, 
differentiate, select and purify 
ESCs. 
Private firm and funded by 
Scottish Enterprise Co-
investment scheme. 
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Figure 3.  Biopharmaceutical Companies in Great Britain24
 
                                                 
24 Senker Jacqueline, Brady Max and van Zwanenberg Paddy,  2000. European Biotechnology Innovation System UK Report, 
SPRU, University of Sussex, Brighton. http://www.sussex.ac.uk/spru/documents/uk.pdf 
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5. Conclusion 
 
As seen the innovation system for biotech is quite vigorous in the UK (see Figure 4.) since the key factors 
industry/supply and knowledge/skills are very strong given the fact that policy makers and firms recognised 
on an early stage the importance of this new technology. Firms make possible the development of user-
supplier relationships and also production chain networks, in which dedicated biotechnology firms can 
contract out the manufacture of new products or clinical trials. 25  
 
Its is interesting to emphasise the importance of small and medium size companies in the industry since these 
firms have managed to be funded and they certainly help to increase the national innovation process in the 
biotech sector. Some of “these firms have now grown to a considerable size and some may even achieve the 
goal of becoming fully-integrated” companies that in the lung run might face de acquisition by larger foreign 
companies. 
 
In recent years large British multinational firms have been restructured and sold to foreign firms (partially or 
totally) as in the case of Astra-Zeneca, formed in 1999 by the merger of the Swedish Astra AB and the 
British Zeneca Group PLC26 which on one hand as an individual firm gained financial stability and global 
market share and positioning but on the other hand the UKs national biotech innovation system lost 
autonomy since now the R&D global headquarters are located in Sweden but nevertheless Britain still 
maintains a solid strength on their science base. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
25 Senker Jacqueline, Brady Max and van Zwanenberg Paddy,  2000. European Biotechnology Innovation System UK Report, 
SPRU, University of Sussex, Brighton. http://www.sussex.ac.uk/spru/documents/uk.pdf   
26 Aztra/Seneca, 2006. http://www.astrazeneca.com/article/11148.aspx 
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Figure 4.  Key Figures of the British Biotech Industry27
 
 
 
                                                 
27 Senker Jacqueline, Brady Max and van Zwanenberg Paddy,  2000. European Biotechnology Innovation System UK Report, 
SPRU, University of Sussex, Brighton. http://www.sussex.ac.uk/spru/documents/uk.pdf  
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b. Spanish Biotech Innovation System 
 
1. Background 
 
Before venturing any further into the Spanish biotech sector it is important to mention the huge disparity with 
this Member State and the rest of the presented countries. There is a lack of information and national 
institutions that tackle issues relevant to our topic of interest. That is why this part is smaller than the sections 
from other countries and is organised in a different way. 
 
There are three kinds of companies devoted to the biotechnology in Spain such as the completely devoted to 
biotechnology which are committed with new breakthroughs and with a clear focus for the scientific and 
technological innovation which most significant sectors are human and animal health, agriculture and food. 
The next type of biotech companies are firms partially devoted to biotech which main area of research 
focuses on the food industry but most of them do not produce but they commercialise products derived from 
modern techniques.  Finally the third division of firms are the ones that use this biotechnology and that again 
operate mainly on the food industry. All of the above groups show homogeneous characteristics within their 
sectors. 
 
Since only the first cluster of firms are devoted to real research we are only going to approach and to study 
this one since it is the only with relevance for this paper. 
 
2. Finances 
 
Between the years 1997-1998 the funds used by these kinds of firms were approximately of € 3,005,060,521 
per year and the average per company was €60 millions but there are certain discrepancies so to make a more 
real figure we can say it is closer to €13.5 millions per company. Exports of biotech firms have been 
declining from € 650,601.613 in 1997 to € 528,403.83 in 1998. Nevertheless the processes and biotechnology 
products have a higher incidence in the export volume in the business as a total, meaning that this market is 
oriented to the foreign market more than to the internal one.28
 
 
28 Díaz Víctor, Muñoz Emilio and Espinosa de los Monteros Juan, 2000. La empresa biotecnológica en España: un primer mapa de 
un sector innovador. Grupo de Ciencia, Tecnología y Sociedad Unidad de Políticas Comparadas (CSIC) 
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The countries to which the exports are done primarily belong to the European Union: 96% of the firms that 
export (27 companies) do it to the EU, and the rest to non EU countries.  
 
Most the these firms (91%) use their own funds in order to finance the high costs that are normal in this 
innovation intensive industry, Public central administration (63,6%) and Autonomous Administration 
(/43,2%). Foreign funds have been used by 18,2% of the firms. 
 
The financial resources are allocated in the internal expenses of R&D as the number one expense followed by 
the acquisition of equipment and machinery and finally external expenses of R&D.  
 
3. Biotech Regulations 
 
Spain is behind the UK regarding local regulations that encourage genetics and stem cell research so firms 
have several legislative proposals in order to increase the development of biotechnology innovation:  
 
• Fiscal incentives policy, grants and co-financing of the biotech centres. 
• Modification of the current laws, specially the Law 14/1994 and the Royal Decree 951/1997 29 since 
they are anachronic and are very bureaucratic preventing the quick responsiveness of this highly 
responsive industry. 
• Equal treatment as other National R&D programmes in order to have same amount of funding. 
• Patent law reform: Reduce the cost and ease the process in order to obtain it. Suppression of ethical 
considerations which should be only considered when exploiting the patent. 
• Modify the scientific policy in order to give more incentives to researchers and to support the link 
between firms and research centres.30 
4. Industry  
 
The Spanish industry began concentrating on this field since the 80s where the Spanish science and 
technology systems were revived and it can be seen in the firms modernisation and then in the product and 
processes incorporation to the national innovation system. This way during 1980–1984 biotechnology firms 
began working (8%) then increasing to 22% between 1985-1989 and then growing to an outstanding 41% in 
the early nineties (period of the fastest growing rate in the sector).   
 
29 Real Decreto 951/1997, de 20 de junio http://www.juridicas.com/base_datos/Derogadas/r0-rd951-1997.html 
30 Díaz Víctor, Muñoz Emilio and Espinosa de los Monteros Juan, 2000. La empresa biotecnológica en España: un primer mapa de 
un sector innovador. Grupo de Ciencia, Tecnología y Sociedad Unidad de Políticas Comparadas (CSIC) 
http://www.iesam.csic.es/doctrab2/dt-0101.htm  
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Most of the firms are privately nationally owned (63 % of the companies) and 31% accounts for privately 
owned multinational firms which are positioned in the food and human health sector (most of them in 
Cataluña and Madrid). The public sector accounts for 6% of the biotech investment. For the national firms 
the biotech research is their principal activity and for the multinationals it is just one more activity but not the 
main one.31
The geographical distribution of these firms is like follow:32
 
Region Number of firms 
Cataluña 42 
Andalucía 27 
Madrid 21 
Comunidad Valenciana 21 
Castilla y León 8 
Aragón 6 
Galicia 5 
Murcia 5 
Navarra 5 
País Vasco 5 
 
 
As seen Cataluña and Madrid are the places where the biggest concentration of firms are found followed by 
Andalucía, Comunidad Valenciana and Galicia. According to the market segments the existing companies 
are divided as “Bio-processes supply firms” (33,6%), “Food” (24,7%) and “Therapeutic: human / animal 
health” (19,9%). Other less important sectors are compiled under “Other health care” (12,3%), “Energy and 
Environment” (6,2%) and “Food: animals” (1,4%) which lack of a solid industrial grid. 
From these previous data it is clearly assumed that the pharmaceutical and food biotechnology sectors are the 
most important in Spain. 
 
These companies totally devoted to the biotechnology have a strong commitment with the innovation 
activities since they are mechanisms to develop changes in the processes and products incorporating new 
strategies and new technology. Eighty percent of these firms have innovated processes and 71% have 
innovated the final product. 
 
                                                 
31 Sociedad Española de Genética http://seg.umh.es/Revistas/revistas.asp 
32 Díaz Víctor, Muñoz Emilio and Espinosa de los Monteros Juan, 2000.  
La empresa biotecnológica en España: un primer mapa de un sector innovador. Grupo de Ciencia, Tecnología y Sociedad Unidad 
de Políticas Comparadas (CSIC) http://www.iesam.csic.es/doctrab2/dt-0101.htm  
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a. Top stem cells firms in Spain 
From the countries studied Spain is the one that runs behind the rest and there were not found any firm 
devoted entirely to the commercialisation of stem cells nor institutes that researched only in this field. The 
newest kind of firms that have something to do with stem cells are the ones in charge of preserving umbilical 
stem cells for future therapy as Smart Cells España which is a joint venture between Laboratorios CR. 
Echevarne and the British Smart Cells International (they are introducing this service with the name of 
“Smartbaby”.33
 
5. Conclusion 
 
The group of biotechnology Spanish firms could be define as an innovative sector that recognises the 
importance of R&D, human resources and cooperation with other similar institutions and that are focused to 
export their processes and products. At the same time if compared with the UK we can see a clear financial 
and legal disadvantage of the industry fact that certainly causes their stem cell national innovation system to 
be far behind from the top EU countries. 
 
It is natural to see why export of their technology (processes and products) is the main focus of the industry 
since researchers don’t have enough national support (legal and financial) and certainly this jeopardises their 
national innovation systems since they are sending away their own R&D. 
 
c. German Biotech Innovation System 
 
1. Background 
 
Germany is a highly-developed and industrialised country that according to the Bundesministerium für 
Bildung und Forschung (Federal Ministry of Education and Research) 50,5% of the industrial production is 
accounted by intensive R&D industries fact that makes it one of the largest world economies which relies on 
this sector (12,2%). Germany leads ahead of Japan (11.5 %), the USA (8.5 %) and the UK (8.0 %). 34
Also regarding the number of patents Germany has the leading position in Europe since the number of 
patents from France and the UK is about half of Germany 
 
33 Smart Cell España http://www.smartcellsespana.com/texto/qservicio.htm 
34 Wörner Stefan, Reiss Thomas,  et al, 2000. European Biotechnology Innovation 
Systems (EBIS) Case Studies Germany. Fraunhofer Institute Systems and Innovation Research. Karlsruhe 
http://www.sussex.ac.uk/spru/documents/germany.pdf 
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The German policy system is traditionally very plural and fragmented if we refer to the national R&D system 
which is based on public research institutions, such as university departments and other public institutes, with 
a diversity of policy players.  The total gross domestic expenditure on R&D amounted to 44,758 million € in 
1998 thus representing 2.33 % of GDP. The German research scene is essentially characterised by three 
sectors: industry, universities and non-university establishments. Since 1994 German business are 
performing more than 2/3 of the R&D budget. The rest of the budget is shared among the higher education 
sector (18 %) and governmental and private non-profit organisations (15 %). However, industry is only 
financing around 61 % of the funds thus profiting from governmental financing of about 36 % of the budget 
which indicates an important disparity of the amount private firms give and take from the resources.35
 
 
2. Funding 
 
The BMG’s departmental research activities are application-oriented and intend to generate knowledge 
related to departmental functions using mainly the following instruments: 
• pilot projects including project funding; 
• departmental research by subordinate institutions and basic funding of non-university research 
institutions (see Figure 1 )  
 
The BMBF (Bundesministerium für Bildung und Forschung) 36  funds several programmes that cover 
biotechnology to some extent. Some of theses specific targeted programmes include clinical trials aiming 
certain diseases. The programme main objectives are to promote health and to combat disease and to improve 
the structures of health research. 
 
The funds of the BMBF focus in 4 important areas: biomedical research, especially basic research and 
research into the causes of disease, clinical research for the improved diagnosis and control of diseases, 
research and development in the field of medical technology and public health research and epidemiology 
including research into health care systems. 
 
 
35 Wörner Stefan, Reiss Thomas,  et al, 2000. European Biotechnology Innovation 
Systems (EBIS) Case Studies Germany. Fraunhofer Institute Systems and Innovation Research. Karlsruhe 
http://www.sussex.ac.uk/spru/documents/germany.pdf 
36 Federal Ministry of Education and Research 
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The priorities of the BMBF are all related to the bio-pharmaceuticals (biomedical research, clinical research 
and medical technology) and are as follow: 
 
The funds that are provided to the Biomedical research are focused in the following fields: 
• “Cancer research: It is funded by the medical departments of universities which in the clinical sector are 
supported by tumour centres. Important contributors in the non-university research sector are the Stiftung 
Deutsches Krebsforschungszentrum and the Stiftung Max Delbrück-Zentrum für Molekulare 
Medizin 
• Cardiovascular research: It is funded by the higher education sector and by non-university institutions 
(Forschungszentrum für Umwelt und Gesundheit) 
 • Molecular medicine: Is funded by the BMBF having prioritising the "Gene therapy I and II"37
 
In Clinical research the Bundesministerium für Bildung und Forschung focuses its funds in the following 
categories: 
• Interdisciplinary clinical research centres 
• Co-ordination centres for clinical studies at universities 
• Competence networks for medicine (MedNet):  
• Infectious diseases: focusing in diseases related emergencies of new pathogens as well as at controlling 
infectious diseases like AIDS and hepatitis and in research within tropical medicine and parasitology. 
 
In the Medical technology division the BMBF’s funding schemes are co-ordinated under the Health 
Research 2000 programme which finances specific programmes on information technology, laser research, 
materials research, microsystems and biotechnology.” 38
 
Besides the above there are several other programmes being funded as The Human Genome Research 
(project) that comprise the following subjects: 
• exploring the structure and function of the human genetic code; 
• developing new possibilities of fighting severe diseases such as cancer, cardiovascular disorders and 
Alzheimer’s disease; 
                                                 
37 Bundesministeriums für Bildung und Forschung,2005.  Forschung und Innovation in Deutschland 2005 
http://www.bmbf.de/pub/forschung_und_innovation_05-07.pdf 
38 Wörner Stefan, Reiss Thomas,  et al, 2000. European Biotechnology Innovation 
Systems (EBIS) Case Studies Germany. Fraunhofer Institute Systems and Innovation Research. Karlsruhe 
http://www.sussex.ac.uk/spru/documents/germany.pdf 
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• establishing new demand-driven technology transfer models 39
(see figure 2 for further information) 
Figure 1: Non-university institution involved in stem cell research.40
 
 
 
 
 
 
 
 
 
 
 
                                                 
39 Wörner Stefan, Reiss Thomas,  et al, 2000. European Biotechnology Innovation 
Systems (EBIS) Case Studies Germany. Fraunhofer Institute Systems and Innovation Research. Karlsruhe 
http://www.sussex.ac.uk/spru/documents/germany.pdf 
40 Wörner Stefan, Reiss Thomas,  et al, 2000. European Biotechnology Innovation 
Systems (EBIS) Case Studies Germany. Fraunhofer Institute Systems and Innovation Research. Karlsruhe 
http://www.sussex.ac.uk/spru/documents/germany.pdf 
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Figure 2. Allocation of some Funds by organisation41
 
3. Biotech Regulations 
 
 
Before going any further with the national biotechnology regulations it is important to emphasize that 
Germany is categorised as having a restrictive policy or no established policy regarding stem cell research. 
“Restrictive policies range from outright prohibition of human embryo research to permitting research on 
imported embryonic stem cell lines only to permitting research on a limited number of previously established 
stem cell lines. Countries with a restrictive policy include (among the most restrictive) Austria, Ireland, 
Norway, Poland, (among the less restrictive) Germany, Italy, and the United States.”42
 
The ministry which has the main responsibility for research policy, the setting up of specialised priorities, 
budgets, and long-term programmes on an aggregate level is the BMBF but also different organisations as the 
Projektträger43 are involved in the administration of most of the countries R&D in tasks that go al the way 
from decision making process, funding consultancy, project assessment and diffusion, publishing and 
evaluating research programmes. (Wörner et al 2000) 
 
It is important to emphasize that given the fact that Germany has a restrictive policy for stem cell research 
there is almost no legislation that tackles with this issue.  
                                                 
41 Wörner Stefan, Reiss Thomas,  et al, 2000. European Biotechnology Innovation 
Systems (EBIS) Case Studies Germany. Fraunhofer Institute Systems and Innovation Research. Karlsruhe 
http://www.sussex.ac.uk/spru/documents/germany.pdf 
42 Hoffman William,  2006. Countries with a permissive or flexible policy on embryonic stem cell research he University of 
Minnesota Medical School http://www.mbbnet.umn.edu/scmap.html 
43 project executing organisation 
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4. Industry  
 
The industry turnover is 1.3 billion € and 59,0% of the firms were established independently, around one 
third grew out of PSR and only some 9 % were founded as a spin-off from another firm. 
 
According to Wörner et al 2000 only 43 % of the firms are older than three years, 61 % have been set up 
between 1994 and 1998. Most of the firms (51 %) achieve 100 % of their total annual sales in biotechnology. 
A relatively large number of companies (23 %) make less than 20 % of their annual turnover in 
biotechnology. Regarding the main product market for 41 % of the firms is Germany, followed by countries 
in the European Union (33 %) and the USA (22 %). This division broadly also applies for services offered in 
biotechnology. Sixty two percent of the firms offer services related to biotechnology, 42 % are contract 
research organisations Almost half of the firms offer their services mainly in Germany and Europe emerged 
to be the main service market to 31 % of the companies and 20 % mainly focus on the US as a market place 
for their services. Only 12 % of the firms reported of licensing income. 
 
Industry overview chart 44
Number of companies 
 
242 
Number of employees 9,450 
Total turnover 1,887 million € 
Total biotech turnover 1,281 million € 
Agencies funding research BMBF, BMG, DFG, AiF, Länder 
ministries, Stifterverband der Deutschen 
Wissenschaft 
Number of dedicated biotech 
institutes 
28 
Regulatory authorities 
 
Bundesinstitut für Arzneimittel und 
Medizinprodukte (BfArM, Federal 
Institute for Drugs and Medical Devices, 
Bonn) 
Regulations Gesetz zur Regelung der Gentechnik (GenTG, 
genetic engineering act) Law on Medical Devices 
(ordinance of medical devices (MPV), ordinance 
on distribution channels for medical devices 
(MPVertrV), ordinance on the mandatory 
prescription of medical devices (MPVerschrV), 
ordinance on the installation, operation and 
application of medical devices (MPBetreibV)) 
Embryonenschutzgesetz (EschG, law about the 
protection of embryos) 
                                                 
44 Statistisches Bundesamt Deutschland  http://www.destatis.de/ 
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a. Top stem cells firms in the Germany 
Given the restrictive policy that the country has towards stem cell research it was not possible to identify 
firms that had their main focus on the stem cell market, that is why only two of the most important and 
relevant stem cell German institutions are mentioned in the chart below.  
 
 
Institution Description Finances 
Max-Planck-Institute of 
Molecular Cell Biology 
Merging molecular cell biology 
with developmental biology 
95% funded by the federal 
government 5% from different 
sources. 
IPK Gatersleben Educational institute Funded by several institutions 
from the German government to 
the EU  and foundations 
 
5. Conclusion 
 
Germany is a clear example of what a lack of the appropriate legislation can do to a whole industry. As stated 
before Germany is the innovation motor in R&D processes of Europe but unfortunately the United Kingdom 
surpasses Germany in the biotechnology / stem cell research and industry since their national legislations 
encourage the innovation systems in this very particular but crucial field. 
The national competitiveness of the country in the biotech sector has the financial support of many public 
and private institutions but nevertheless some large German biotech pharmaceuticals had decided to locate 
part of the R&D labs in other member states or even outside of the union due to legal reasons. 
 
d. Dutch Biotech Innovation System 
 
1. Background 
 
The Netherlands is one of Europe’s smaller member states with a high income having a very strong 
agricultural and food sector followed by the petro-chemical one, nevertheless the total public spending on 
R&D is rather low, compared to other Member States. 
Nevertheless the biotechnology sector is one of the most important from an international perspective. In the 
Netherlands three multinational companies are located that are also active in biopharmacy: AKZO Nobel (a 
Dutch Global Fortune 500 Company based in the Netherlands)45, DSM (a nutritional and pharma ingredients, 
                                                 
45 Akzo Nobel, 2006. Our Company. http://www.akzonobel.com/com/Our+company/aboutakzonobel.htm 
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performance materials and industrial chemicals. company with headquartered in the Netherlands) 46  and 
Solvay Pharmaceuticals (Dutch based pharmaceutical and chemical firm). Then there is Pharming, firm that 
develops protein therapeutics for unmet medical47 needs using pharmaceuticals in transgenic animals. The 
following chart48 gives a better overview of the Dutch national biotech perspective. 
 
                                                 
46 DSM, 2006. Company Profile http://www.dsm.com/en_US/html/about/company_profile_2006.htm 
47 Pharming Group N.V.,2006.  http://www.pharming.com/ 
48  S. Kern & C. Enzing, 2002. The Dutch Biotechnology Innovation System: An inventory and assessment of the major 
developments since 1994. Netherlands Organisation for Applied Scientific Research  
http://www.sussex.ac.uk/spru/documents/netherlandscountryreport.pdf  
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2. Funding 
 
The Dutch public biotechnology funding system is quite large and diverse and focuses in many areas of 
medical development note exclusively focusing in genetics and stem cell research that is why we are going to 
focus only in the specifics that have to do with our area of study. Nevertheless the general funding system is 
going to be explained by a chart (figure 1). 
 
Most public funds come from governmental ministries, the rest from industry and charities. The funds find 
their way through so-called intermediate organisations to the research groups in the R&D infrastructure. 
These organisations exist of academic research organisations, such as the universities, the KNAW (Royal 
Academy of Science) and NOW (Netherlands Organisation for Scientific Research) institutes and applied 
research institutes such as TNO (Netherlands Organisation for Applied Scientific Research), DLO 
(Directorate Agricultural Research) and RIVM (National Institute of Public Health and Environmental 
Protection).  
 
The main funding organisations of biopharmaceutical research are the Ministry of Education, Culture and 
Science and the Ministry of Economic Affairs, funding through the NOW and other programmes (see 
figure1).  
 
The Ministry of Education, Culture and Sciences also funds certain programmes specifically targeting 
medical faculties from different universities and institutes (where more than 1400 researchers and staff are 
funded).  In the biopharmaceutical field funding is acquired by the Council of the Medicinal Sciences 
(Medische Wetenschappen: NWO-MW).  
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Figure 149: Total of funding activities for public R&D activities on biotechnology 
 
 
“The average annual budget of the MW-division is ca. Euro 3.22 million. In addition to the open calls, the 
NWO has special programs. The Human Genome project of NWO started as a special program 
(Prioriteitsprogramma) focused on hereditary diseases, including the ethical and social aspects had a total 
budget of Euro 5.8 million; Euro 5.58 million was NWO money, the rest was co-financed by the Ministries 
of OC&W, of Public Health and the EU BIOMED program. 
 
The Foundation for Life Sciences finances biopharmaceutical research in Bio-molecular structures and 
processes and Neuronal, endocrine process regulation and developmental biology. The Foundation for 
Chemical Research in the Netherlands supports bio-pharmaceutical research into the biochemical aspects of 
medicine in key topics as:  
• Nucleic acids 
• Molecular genetics 
                                                 
49  S. Kern & C. Enzing, 2002. The Dutch Biotechnology Innovation System: An inventory and assessment of the major 
developments since 1994. Netherlands Organisation for Applied Scientific Research  
http://www.sussex.ac.uk/spru/documents/netherlandscountryreport.pdf  
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• Protein research 
 
One of the most important charities that funds biopharmaceutical research is The Dutch Cancer Society with 
approximately € 42,8 million per annum most of which was spend by the Dutch Cancer Institute affiliated to 
the Anthonie van Leeuwenhoek Hospital in Amsterdam.”50
 
Overall most of the biotech funding comes from private institutions or firms (the latest not reflected on any 
numbers or figures on this paper) since for such a small country the Netherlands has some very large biotech 
firms. 
 
3. Biotech regulations 
 
In the early 1990s, the Dutch regulations on the biotech field were one of the most advanced in the world 
(especially with the Dutch Decree on Novel Foods). Later on several debates were held rising questions 
about safety and financial issues. As a result the regulations shown on figure 2 were obtained: 
 
 Figure 2: Specific Dutch regulations and laws concerning biotechnology activities 
 Law/ regulation Responsible 
ministry 
Aspects covered 
Contained use 
 
-General Nuisance 
Act 
-Chemical 
Substances 
Act, Decree on 
GMO51s 
-EU Regulation no. 
90/219 on contained 
use 
 
Ministry of 
Public Housing, 
Infrastructure 
and 
Environment 
 
Contained work with 
GMOs, covering 
workplace, 
experiments with 
GMOs 
 
Environmental 
release 
 
-Chemical 
Substances 
Act, Decree on 
GMOs 
-EU Regulation 
90/220 
on deliberate release 
 
Ministry of 
Public Housing, 
Infrastructure 
and 
Environment 
 
Deliberate release of 
GMOs into the 
environment, 
experiences with 
GMOs 
 
                                                 
50 S. Kern & C. Enzing, 2002. The Dutch Biotechnology Innovation System: An inventory and assessment of the major 
developments since 1994. Netherlands Organisation for Applied Scientific Research  
http://www.sussex.ac.uk/spru/documents/netherlandscountryreport.pdf  
51 Geneticaly Modified Organisms  
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Market 
introduction 
 
-Commodities Act, 
Decree on Novel 
Foods 
-EU Regulation no. 
258/97 on Novel 
Foods 
-Drugs and 
Diagnostics Act 
 
Ministry of 
Public Health, 
Welfare and 
Sports 
 
Consumer safety and 
information with 
respects to foods, 
food ingredients, 
beverages, drugs and 
diagnostics; 
 
Biotechnology 
with animals 
 
- Animal 
Experiences Act 
- Animal Health and 
Welfare Act 
- Decree on 
Biotechnology with 
Animals 
 
Ministry of 
Agriculture, 
Nature 
Management 
and Fisheries 
 
Genetic 
modification of 
animals and animal 
experiences 
 
Working 
conditions 
 
- EU Directive no. 
90/679 
- Decree on 
Biological 
Agents 
 
Ministry of 
Social Affairs 
and 
Employment 
 
Exposure of 
employees to 
biological agents 
(among these 
GMOs) 
 
S. Kern & C. Enzing, 2002 
 
Regarding the policy concerning biotechnology, the attitude of the Dutch Government, under pressure of the 
Parliament, always has been one of opposition to patenting plants or animals. During the many years of 
debate on a European level about a directive on patenting biotechnology inventions, the Netherlands have 
taken many efforts to make their objections known to the European Member States. Trying to avoid the 
patents of animals and plants in 1998 a new law was approved prohibiting the patenting of these organisms.  
 
A major setback was the approval by the European Parliament and the European Council of Ministers of the 
directive on patenting biotechnology discoveries and the Netherlands was forced to alter the current 
legislation and allow the legal protection of biotechnology research results, being the only member state that 
voted against it. 
 
The Dutch government has always been against the patent for life and constantly defying the community 
directives or laws that grant some sort of patent or exclusivity for life related (genetic) issues. The most 
interesting fact is that this view is solely shared by the government and parliament but not by the industry 
which is on favour of such laws or directives. 
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4. Industry 
 
The Dutch pharmaceutical industry consisted of 115 companies 52 ; 5 companies produce intermediates 
products and the rest produce actual biopharmaceutical related products fact that shows how intensive this 
industry is in the country. In 1998 the annual turnover of this sector was of €1,140 million, increasing in an 
amount of 12,4% from the previous year. The international commerce had a surplus and grew 21,8% and 
from this amount 90,0% was made within European countries.  
 
In order to further have a general image of the Dutch biotechnology industry it must be divided by indicators 
such as size, activities, sources of technology, turnovers, markets and products, and supplies; which will be 
explain in the following paragraphs: 
 
• Size and biotechnology activities 
The biggest amount of biopharmaceutical firms in the country is made up by small companies which have 
less than fifty employees. One fifth of the actual firms account for large firms which also perform R&D as 
their core activity. Approximately a third of the firms combine R&D activities with other activities, mostly 
with production. Furthermore it is very interesting to learn that the size of the firm (smaller) is correlated 
with the amount of trade/distribution, consultancy and services, meaning that larger firms do not perform 
these activities. 
• Type of biotechnology firms and its technological sources 
There are three types of firms: 
o Diversified firms: one third of the total number of Dutch firms. 
o Dedicated firms: accounts for two thirds of the market. 
o Prototype firms: number too small to be significant. 
During the 90s the biopharmaceutical industry grew at a very fast pace doubling the growth rate of the agro-
food and equipment sectors. 
Licenses are a very important and critical issue for biotechnology firms and most licenses hold by Dutch 
firms come from the USA (approximately two thirds) and in spite the fact that there is a large number of 
firms holding Dutch patents the firms that actually produce the largest source of technology are the ones 
owning US based patents. 
Most equipment for the firms is purchased from the USA, Europe and from the Netherlands. 
• Ownership and turnover 
 
52 Statistical data from late census 1998 
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The majority of the bio firms in the Netherlands are domestically owned (3:5 ratio), and in some cases 
subsidiaries also have certain amount of national ownership. From this we can conclude that the Dutch 
biotech industry is indeed dominated by domestic investors. (See figure 3 for further information) 
 
Figure 3: Turnovers of Dutch, EU & USA based firms 
Type of firm Total turnover Biotech turnover 
Domestic € 457,00 millions € 193,00 millions 
Independent € 149,00 millions € 126,65 millions 
Subsidiaries € 308,00 millions €   67,76 millions 
7 EU & USA based firms € 216,00  
3 EU firms  €     7,00 millions 
4 USA firms  € 104,00 millions 
S. Kern & C. Enzing, 2002 
 
The previous chart gives a clear image of the market turnovers and special attention should be taken to the 
biotech turnover of the subsidiaries if compared with the independent firms since it is two times smaller in 
spite that their total turnover is the double of the independent ones. This can be attributed to the fact that most 
of the domestic subsidiaries are trade and sales firms in comparison with the independent companies (start-
ups) 
Products and markets: 
The national income from the biotech companies rounds about the €673 million averaging twenty six million 
euros per firm. The biotechnology earnings from product manufacturing and provision of services is about 
€291 million (43% of the total proceeds). 
We can appreciate from the numbers that the national (Dutch) market is not the most important market for 
any of the biopharmaceutical organisation since 2/3 of all biotech companies market their products abroad.53
a. Top stem cells firms in The Netherlands 
As in the case of Germany, The Netherlands given its very restrictive policy for stem cell commercialisation 
lacks of firms devoted to this kind of endeavours. Nevertheless there are biotechnological firms which as in 
the case of the UK have been spin-off universities like the Leiden Amsterdam Centre for Drug Research and 
the Leiden Institute of Chemistry both from the Leiden University. There are also spin-off firms from other 
                                                 
53  S. Kern & C. Enzing, 2002. The Dutch Biotechnology Innovation System: An inventory and assessment of the major 
developments since 1994. Netherlands Organisation for Applied Scientific Research  
http://www.sussex.ac.uk/spru/documents/netherlandscountryreport.pdf  
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Dutch universities like Maastricht, Ultecht, Groningen and Twente (which are the biggest universities in the 
country. 
5. Conclusion: 
 
The Dutch biotechnology system is quite interesting and peculiar since on hand has they have a very 
energetic industry with many firms which certainly innovate and create added value for the national biotech 
knowledge pool as well as international (since they trade this technology and rely on other countries as well) 
but on the other hand they have a very conservative national policy that is concern with the patenting of life 
(not only human but animal and vegetal). 
The industry has managed to flourish given the commissions biotech directive that was enforced to all 
Member States and that there hasn’t been a real commitment by Dutch law makers to stop this important 
industry in the country (although their very conservative thoughts and approaches). Basically companies 
have been able to pursue their interests in this country using the legal ambiguity of the union’s legislation and 
national legislation. 
 
e. Countries comparison chart54 
The following chart represents a summary of the description of the above countries emphasizing the national 
regulatory environment, the source of the fund (funding system) and the main therapies which are allowed 
and been developed. 
 
Germany 
Regulation framework Human embryo stem cell activities are 
very restricted (almost forbidden), 
although the new Merkel administration 
seems to be more open to this than the 
past one. 
Funding General funding from the Federal 
Government allocated to biotechnology. 
There is no government funding for stem 
cell research. 
Types of research Restrictive human embryonic stem cells 
and adult stem cell. 
Industry Has the second largest biotech / genetics 
industry in Europe just surpassed by the 
UK.  High in equipment and suppliers 
and biopharmaceuticals. Focuses on the 
national and European market. 
Stem cell Companies Research institutes (no firms) Max-
                                                 
54 Perrin Nicola, 2005. The Global Commercialisation of UK Stem Cell Research. UK Trade and Investment. 
http://www.fco.gov.uk/Files/kfile/UKTIStemCellsReportAugust2005,0.pdf 
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Planck-Institute of Molecular Cell 
Biology & IPK Gatersleben
Netherlands 
Regulation framework Most embryonic research is guided by the 
Embryos Act but the use of embryonic 
stem cells is restricted. This policy will 
be reviewed next year (2007) by the 
government. 
Funding Government is granted by universities 
and research clusters.  
Main therapies allowed Human embryonic stem cells and adult 
stem cell. 
Industry  Is the third largest biotech / genetics 
industry just behind Germany, no stem 
cell industry. Very high on equipment 
and suppliers and less high in 
biopharmaceuticals. Primarily focused on 
tissue engineering. Focused on the 
European market. 
Stem cell Companies No firms but only genetics institutions 
(spin-offs from universities) 
Spain 
Regulation framework We can say that Spain has a legislation in 
progress since it is expected the 
parliament to pass a new legislation that 
would allow (within very specific cases) 
stem cell research. 
Funding With this new legislation the government 
is looking forward to increase funding 
considerably in two clusters that are 
expected to be in Cataluña and Valencia. 
Main therapies allowed Human embryonic stem cells and adult 
stem cell. 
Industry Has the weakest biotech /genetics 
industry from the chosen countries, no 
stem cell industry (but it’s supposed to 
change given modifications to the law 
later on 2006). Concentrates on 
producing consumables and imports 
technology, European market focused.  
Stem cell Companies No firms but some biotech clusters 
United Kingdom 
Regulation framework Allows embryonic and adult stem cell 
research and its legislation is regarded as 
one of the more advanced in the world. 
(Comprehensible, accountable and 
precise). 
Funding The stem cell research is funded by 
charities, research councils and the 
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government. 
Main therapies allowed Somatic cell nuclear transfer, human 
embryonic stem cells and adult stem cell. 
Industry It leads Europe (and the world according 
to some studies) given the high 
investment and laws. Biggest European 
stem cell industry (virtually the only 
one) . Six leading centres. Focuses on 
providing the national market as well as 
the European one. 
Stem cell Companies Axordia, CellCentric, EpiStem, 
Intercytex, Novathera, Odontis, 
RegenTec, Reinnervate, Reneuron, 
Renovo, StemCellSciences. 
 
f. Conclusion 
 
According to the Final Report European Biotechnology Innovation Systems Germany, The Netherlands and 
UK have a well-developed biotechnology equipment and supplies sector. These countries maintain numerous 
institutions devoted to scientific research and education.  There is also considerable investment in research by 
various multinational chemical and pharmaceutical companies in these countries, as well as a growing 
population of new biotechnology firms. National research activity provides both a market for equipment and 
supplies and may also stimulate the development of new generations of products. The national German and 
UK market are growing (specially the British one) but its sustainability could be jeopardised by the lack of an 
adequate policy (specially the German) by other non European countries. The businesses in The Netherlands 
have strong links to firms in other countries which may compensate for the relatively small domestic market.  
 
The country that has the strongest national innovation system in the stem cell industry is the UK given the 
fact that is the only one that has firms devoted solely to the stem cell research and commercialisation; most of 
these companies had been spin-offs from different universities within the country (making its national 
innovation processes highly integrated). 
 
Nevertheless all of the above countries have very different national policies and attitudes towards stem cell 
research and with the lack of a stem cell European legislation UK is the one taking advantage by having 
national laws that enables them to be ahead of the research and patents, next comes The Netherlands not 
because of the politicians and policy makers attitude towards the issue but because of the lack of 
responsiveness in tackling the matter with some restrictive national law, thus firms are capable to gain in the 
Dutch market and finally Germany since it has a restrictive stem cell and genetics policy. 
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The country that is behind (from our four studied member states) is Spain since public research funding is 
low compared to other countries, thus hampering demand and the development of a large pool of creative 
scientists. In addition, it has few biotechnology firms in the equipment and supplies sector, and though Spain 
has R&D-performing subsidiaries of multinational pharmaceutical companies. Also there are many concerns 
by the industry regarding the lack of national legislation that promotes R&D in this particular field since 
Spain traditionally is a country with little or no industrial activity in equipment and supplies (engineering and 
development of instrumentation). Fortunately a new legislation is expected to be approved by the parliament 
that would allow stem cell research and would enable funding to be available. 
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5. Patents  
a. Background 
 
The first attempt to protect new products or processes was The Paris Convention55 (1883) which is an 
international convention for promoting trade among the member countries, devised to facilitate protection of 
industrial property simultaneously in member countries without any loss in the priority date. This was the 
first time when issues regarding patents, utility models, industrial designs, trademarks, unfair competition, 
national treatment and parallel imports were addressed by the international community as a whole56. 
 
After the Paris Convention was signed by different countries The Patent Cooperation Treaty (PCT) (1970) 
came as a very important tool to patent a product or process in many countries at once. In spite the fact that 
the PCT does not automatically issue patents in all the world it does provides important protection and 
benefits for the applicant of the patents (specially from foreign countries). Basically the PARIS Convention 
and the PCT work together given the fact that the PCT allows applicants of a patent to apply directly into the 
member countries from the Paris Convention up to one year since the initially files for the patent in the own 
country with a reasonably fee.57
Later on in 1973 The European Patents Convention (EPC) was created that gave birth to the EPO (European 
Patent Organisation), this way a European patent is converted into a collection of enforceable and revocable 
patents. It is important to emphasize that currently there is not a single EU patent, still it must be done the 
regular way but recently many questions have been addressed to propose a single EU wide patent that would 
not only protect inventions across the Union but across the world in conjunction with the PCT.58
So far all of these agreements or treaties have been dealing with general patents until in 1977 The Budapest 
Treaty on the Recognition of Deposit of Microorganisms was signed and here the main feature of the Treaty 
is that a “contracting State which allows or requires the deposit of microorganisms for the purposes of patent 
procedure must recognize, for such purposes, the deposit of a microorganism with any “international 
 
55 Lidgard Hans Henrik, 2006. IPR, Biotech & Technology Transfer Legislation. Juridiska Fakulteten vid Lunds Universitet. 
56 Patents Facilitating Centre, 2006. Paris Convention. International conventions and treaties 
http://www.tifac.org.in/do/pfc/pub/conven/paris.htm 
57 Eisenberg Howard M., 2001. Patent Law You Can Use , Patent Cooperation Treaty (PCT). Yale University Office of 
Cooperative Research. Yale University, New Haven, USA. http://www.yale.edu/ocr/invent_guidelines/docs/PCT.pdf  
58 Legislative Initiatives in European Patent Law, 2006. Community Patent European Patent Office  
http://patlaw-reform.european-patent-office.org/community_patent/ 
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depositary authority”59”, without taking into consideration of the geographical position of the authority. This 
Treaty makes the patent system of the contracting State more attractive because it is primarily advantageous 
to the depositor if he is an applicant for patents in several contracting States; the deposit of a microorganism 
under the procedures provided for in the Treaty will save him money and increase his security. The Treaty 
increases the security of the depositor because it establishes a uniform system of deposit, recognition and 
furnishing of samples of microorganisms.60  
Finally the most recent international conventions to tackle with human medicine and protection of inventions 
were in The Convention on Biological Diversity (1992) and the Convention on Human Rights and 
Biomedicine (1997)61 which is only mention since they are very broad and only compliment the previous 
conventions that really address patents.  
b. Purpose 
 
According to Nielsen & Whittaker a general patent law aims to promote technical innovation and the 
dissemination of its fruits. The inventor gets exclusive rights to control commercial exploitation of his 
invention for some years and in return, he discloses detailed description of his invention, making the new 
knowledge available to all. This disclosure enables others (researchers etc…) to build on the achieved 
knowledge.”62 Also it is important to mention here the 1998 EU Directive regarding legal protection of 
biotechnological inventions which original purpose is to establish legal certainty in this area within the 
European Community and to help European biotechnological companies to become more efficient in 
promoting innovation and thus attracting investment. 
 
c. Definition 
 
The European Commission defines a patent as a protection provider to the patent holder; this protection 
normally is granted for 20 years, given the holder of the patent exclusivity on the commercialisation and 
exploitation. At the same time a patent prevents third parties from using or reproducing such invention 
 
59 is a scientific institution - typically a “culture collection” - which is capable of storing microorganisms 
60Budapest Treaty on the International Recognition of the Deposit of  
Microorganisms for the Purposes of Patent Procedure, 1980. World Intellectual Property Organization 
http://www.wipo.int/treaties/en/registration/budapest/index.html 
61 Lidgard Hans Henrik, 2006. IPR, Biotech & Technology Transfer Legislation. Juridiska Fakulteten vid Lunds Universitet. 
62 Nielsen Linda & Whittaker Peter, 2002. Ethical Aspects of Patenting Inventions Involving Human Stem Cells. Pg. 6 Opinion of 
the European Group on Ethics in Science and New Technologies to the European Commission. Brussels.  
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(within very specific guidelines). n case that any given third party wants to use such patent there must be a 
common agreement between the holder of the patent and them (normally called a licence.)  
The granting of a patent is not an authorisation for the use of the invention. As mentioned in recital 14 of the 
Directive63  ...“a patent for invention does not authorise the holder to implement that invention, but merely 
entitles him to prohibit third parties from exploiting it for industrial or commercial purposes”. It is important 
to emphasize that a patent is not a legal title that grants its holder the exclusive right to exploit an invention 
nor it is a right of ownership. 
  
 
 
 
 
 
63 The European Parliament and the Council of the European Union, 2004. Directive 2004/23/EC Of The European Parliament And 
Of The Council on setting standards of quality and safety for the donation, procurement, testing, processing, preservation, storage 
and distribution of human tissues and cells. Official Journal of the European Union http://europa.eu.int/eur-
lex/pri/en/oj/dat/2004/l_102/l_10220040407en00480058.pdf  
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6. Patenting Involving Human Stem Cells  
a. Patents on human embryonic inventions 
 
As mentioned previously in the field of biotechnology it is very important to distinguish between a regular 
discovery and invention from the rest of the other fields since even the description of the patented product or 
process may be difficult for reasons that had and will be discussed.  That is why the Budapest Treaty was 
very handy since it states the necessity of a depositary authority which will define the micro-organism by the 
national law of the country where such depositary is. 
 
Nonetheless it is not sufficient the term micro-organism by itself since it’s a very vague term and nowadays 
there are different processes (PRC) and products (PRD) which have been considered for patenting such as: 
 
• “Isolation of stem cell from embryos or tissues (PRC) 
• Culturing of stem cells (PRC) 
• Enrichment of stem cells in mixture of cells (PRC) 
• Genetically modifying stem cells for particular applications. E.g. to avoid rejection after a 
transplantation (PRC) 
• Inducing stem cells to differentiate in particular ways (PRC) 
• Inducing adult stem cells to undergo retrodifferentiation or transdifferentiation 64  with limited 
differentiation capacity towards multipotency or pluripotency. (PRC) 
• Create embryos by transfer of a somatic cell nucleus to an enucleated (lacking of a nucleus)65 egg for 
derivation of stem cell, giving the possibility of producing autologous stem cells which are lees likely 
to be rejected. (PRC) 
• Create non-viable embryos by parthenogenesis66, eliminating the need to destroy potentially viable 
embryos for deriving stem cells. (PRC) 
• Transforming somatic cells directly into stem cells, e.g. by injecting them with stem cell cytoplasm or 
egg cytoplasm67. (PRC) 
• Stem cells (PRD) 
• Stem cell lines (PRD) 
 
64 Transdifferentiation or retrodifferentiation is the induction of adult stem cells to differentiate into cells of a tissue type different 
from that normally associated with the particular stem cells. 
65 The American Heritage® Stedman's Medical Dictionary, 2nd Edition http://medical-dictionary.thefreedictionary.com/enucleated 
66 form of reproduction in which an unfertilized egg develops into a new individual 
67 also called ooplasmic transfer 
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• Differentiated stem cells (PRD) 
• Genetically modified stem cells. (PRD)”68 
 
As seen all these processes and products are quite complex and in some ways very similar but the scope of 
them might focus in very different outcomes, it’s of paramount importance not to underestimate the 
significance of all the patentable processes since it isn’t now but in some decades where the real human 
benefit of all these therapies will be seen and applied to the general public.  So far stem cells from a human 
embryo have been isolated in the US, Australia, India, Singapore, Israel, Sweden and the UK and cultured 
only in the UK (given its legislation and technology). It is an undeniable fact that such patents have already 
been granted in the US (see annexe d.) and that given the lack of legislation and decisiveness of the 
commission the UE is running behind the US on this topic. 
 
While the EU policymakers still debate whether patents on human embryonic stem cells should be granted or 
not given the fact that specially in recent years all these genetic patents have raised a lot of questioning and 
concerns. Given the actual legislation it is not likely to have a patent law that tackles with the stem cell issues 
taken from the conventional patent law. As it is unlikely that patents for genetic inventions will be carved out 
from patent law. That is why there are alternatives that would help stem cell patents to be feasible right now 
without the need to wait for a more decisive Commission of the whole change of patent law. These 
alternatives are explored in order to focus on solutions for the European stem cell lack of legislation for this 
specific kind of patents: 
 
• Exemptions69: One possibility for guaranteeing the freedom to use patented technology is to exempt 
certain activities from infringement. An example of this is the research or experimental use exemption 
that qualifies scientific research for immunity from infringement which is part of patent law laid 
down in the Community Patent Convention (see the 89/695/EEC Luxemburg Convention), which 
states in its article 27 that the rights that are conferred by a patent shall not extend to section (b) “acts 
done for experimental purposes relating to the subject-matter of the patented invention70”. By this 
way it is possible to use the current legislation on favour of the stem cell research without infringing 
 
68 Nielsen Linda & Whittaker Peter, 2002. Ethical Aspects of Patenting Inventions Involving Human Stem Cells. Opinion of the 
European Group on Ethics in Science and New Technologies to the European Commission. Brussels.  
69 Van Overwalle Geertrui et al, 2006. Models for facilitating access to patents on genetic inventions Nature reviews. Genetics 
Journal  
http://www.lub.lu.se/cgi-
bin/ipchk/http://elin.lub.lu.se/link2elin?genre=article&issn=14710056&year=2006&volume=7&issue=2&collection=ejor&pages=
143-154&resid=c1c966523071882b9a0c413f4286f9be&lang=en
70 European Council, 1989. Agreement relating to Community patents  89/695/EEC, Luxemburg  
http://europa.eu.int/eur-lex/lex/LexUriServ/LexUriServ.do?uri=CELEX:41989A0695(01):EN:HTML 
 51 
                                                
the law. At a national level most some member states mimic this approach taken at a community level 
and some don’t so still it is important to check Member States legislations to see if this approach is 
possible. 
 
• Licensing agreements: This is one of the most common used instruments for activities that cannot be 
covered by the previous research exemption. Here the licensor and licensee have considerable 
freedom to choose the appropriate contract modalities and clauses as long as they do not have an anti-
competitive effect. Royalties and transaction costs might be reduced to a minimum by negotiating 
cross licences. Cross licensing might be attractive in various settings, including cases of 
complementary patents and blocking patents. The exchange might concern more than two patents, or 
in some cases even entire portfolios71. Unfortunately these kinds of agreements are only useful for 
entities with assets for them to exchange or offer in return thus being a restrictive option for firms 
with no or few leverage. 
 
• Patent pools: This option might be a title bit more complex than the previous one but its fairly simple, 
a patent pool is just is basically and agreement between two or more firms or entities who own 
patents to licence their patents to one another or to license them to third parties. This licence can be 
provided directly by the owners of the patent or by a newly created entity devoted to managing the 
pool.  
 
• Compulsory licenses: “Under this mechanism the government or a court can compel a patent holder 
to license his rights. The 1994 worldwide WTO (World Trade Organization) Agreement on Trade 
Related Aspects of Intellectual Property Rights affirms the right of member states to grant 
compulsory licences and implicitly confirms their current autonomy to determine the grounds on 
which such licences can be granted. Normally compulsory licenses are granted in cases of 
dependency of a downstream patent holder on an upstream patent holder, and in cases in which the 
invention is not (or insufficiently) exploited. Recently, it has been suggested that the compulsory 
licensing mechanism can be invoked to address the potential hindering effects of patents in public 
health care. In this regard, the European Union has  a very advanced vision since they compulsory 
 
71 Van Overwalle Geertrui et al, 2006. Models for facilitating access to patents on genetic inventions Nature reviews. Genetics 
Journal
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licenses have been put for work for public health benefit of developing countries and also countries as 
France and Belgium have implemented licences for domestic public health issues.” 72 
b. Ethics and law 
 
So far it’s clear that all member states have diverse approaches towards the legal background that enables 
their different national innovation systems (institutions) to research and make real progress in this R&D 
intensive field. Nevertheless before tackling any other issue it’s important to recognise the huge ethical 
matters that arise given the sensitiveness of the topic. 
In order to approach briefly the community law and issues that tackle with stem cell ethics it’s important to 
refer to the Opinion of the European Group on Ethics in Science and New Technologies to the European 
Commission in their document No 15 where four main topics are identified as follow:73
 
“Human stem cell research is an example of bioethical value conflicts.  On the one hand, the prospect of 
new therapies, even in the far future, is attractive in offering an alternative to organ and tissue donation. On 
the other hand, when this research involves the use of human embryos, it raises the question of its ethical 
acceptability and of the limits and conditions for such research. Embryo research has been extensively 
debated in the context of research carried out to improve IVF as a treatment for infertility. Embryonic stem 
cell research raises the following specific additional ethical questions: 
 
New type of research to be performed on human embryos. Up until now, research that involved 
destroying embryos, if allowed, was limited to research on reproduction, contraception or congenital 
diseases. With human stem cell research, a much wider scope of research is being considered. 
 
The use of ES cells and stem cell lines for therapeutic purposes. Human embryos used for research were 
destroyed after the research was completed and therefore were never used for fertility treatment. What 
remained was additional knowledge. Human embryonic stem cell research is aimed at creating cell lines with 
appropriate characteristics, in terms of purity and specificity. There is thus continuity from the embryonic 
cells to the therapeutic material obtained by culture. 
 
 
72 Van Overwalle Geertrui et al, 2006. Models for facilitating access to patents on genetic inventions Nature reviews. Genetics 
Journal
73 McNally Eryl & Cambon-Thomsen Anne, 2004. 25 Recommendations on the ethical, legal and social implications of genetic 
testing. European Commission. Brussels 
http://europa.eu.int/comm/research/conferences/2004/genetic/pdf/recommendations_en.pdf  
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The creation of embryos for research purposes. This delicate issue is now raised again since there is a 
scientific justification of this practice, namely the possibility of producing stem cells identical to the patient’s 
cells and thus avoiding problems of rejection in the context of the future “regenerative medicine”. At the 
same time, creating human embryos raises new ethical concerns. The ethical acceptability of stem cell 
research depends not only on the objectives but also on the source of the stem cells; each source raising 
partly different ethical questions. Those who condemn embryo research in general will not accept this 
difference, but for those who accept it, this issue is of major importance.  
Issues in transplantation of stem cells. Clinical research and potential future applications in this field raise 
the same ethical issues as those dealt with in the EGE’s Opinion on Human Tissue Banking (21/07/1998), 
concerning the respect of the donor, who should give informed consent to this use of the donated cells, the 
respect of the autonomy of the patients, their right to safety and to the protection of their private life and the 
right to a fair and equal access to new therapies74; and more recently on the EGE´s Opinion on The Ethical 
Aspects of Human Tissue Engineered Products (29/06/2004), where there is yet no European legislation 
specifically and comprehensively covering the authorisation to put human tissue engineered products on the 
market.75 ”76
Given the paramount importance of the previous problems it is important to recognise that from a legal point 
of view the principles of individual autonomy, human dignity, justice and proportionality are the ones in 
stake and as Article 22 of the Charter on Fundamental Rights on Cultural, religious and linguistic diversity 
that reads: 
“Conscious of its spiritual and moral heritage, the Union is founded on the indivisible, universal values of 
human dignity, freedom, equality and solidarity; it is based on the principles of democracy and the rule of 
law. It places the individual at the heart of its activities, by establishing the citizenship of the Union and by 
creating an area of freedom, security and justice. 
The Union contributes to the preservation and to the development of these common values while respecting 
the diversity of the cultures and traditions of the peoples of Europe as well as the national identities of the 
Member States and the organisation of their public authorities at national, regional and local levels; it seeks 
to promote balanced and sustainable development and ensures free movement of persons, goods, services 
 
74 McLaren Anne, Hermerén Göran. Ethical Aspects of Human Stem Cell Research and Use 14 Nov. 2000, Opinion of the 
European Group on Ethics In Science and New Technologies to the European Commission 
75 Report of the European Group on Ethics on the Ethical Aspects of Human Tissue Engineered Products. 2004. 
http://europa.eu.int/comm/european_group_ethics/docs/humantissueprod.pdf  
76 McNally Eryl & Cambon-Thomsen Anne, 2004. 25 Recommendations on the ethical, legal and social implications of genetic 
testing. European Commission. Brussels 
http://europa.eu.int/comm/research/conferences/2004/genetic/pdf/recommendations_en.pdf 
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and capital, and the freedom of establishment. To this end, it is necessary to strengthen the protection of 
fundamental rights in the light of changes in society, social progress and scientific and technological 
developments by making those rights more visible in a Charter.” and with Article 6 of the Amsterdam Treaty 
(see annexe c.) which ensures the protection of fundamental rights at UE level based on traditional 
international instruments stressing the respect for national identity of all Member States. 
Also it is important to recognise the base of the legislation that enables the rest to lie over it in regards of the 
health and R&D. Article 152 of the EC Treaty on public health that states “a) measures setting high 
standards of quality and safety of organs and substances of human origin, blood and blood derivatives; these 
measures shall not prevent any Member State from maintaining or introducing more stringent protective 
measures;”77. The previous clearly recognises the autonomy of the MS to create their own public health 
legislation in order to ensure protection to their citizens. Article 163 of the EC Treaty on research and 
technological development states “1. The Community shall have the objective of strengthening the scientific 
and technological bases of Community industry and encouraging it to become more competitive at 
international level, while promoting all the research activities deemed necessary by virtue of other chapters 
of this Treaty.” 
2.   For this purpose the Community shall, throughout the Community, encourage undertakings, including 
small and medium-sized undertakings, research centres and universities in their research and technological 
development activities of high quality; it shall support their efforts to cooperate with one another, aiming, 
notably, at enabling undertakings to exploit the internal market potential to the full, in particular through the 
opening-up of national public contracts, the definition of common standards and the removal of legal and 
fiscal obstacles to that cooperation. 
3.   All Community activities under this Treaty in the area of research and technological development, 
including demonstration projects, shall be decided on and implemented in accordance with the provisions of 
this title.” and article 173 of the EC Treaty certainly binds the technological development to the commissions 
consideration since “At the beginning of each year the Commission shall send a report to the European 
Parliament and to the Council. The report shall include information on research and technological 
development activities and the dissemination of results during the previous year, and the work programme 
for the current year.” 
 
77 Consolidated Version Of The Treaty Establishing The European Community, 2002. http://europa.eu.int/eur-
lex/lex/en/treaties/dat/12002E/htm/12002E.html  
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c. Patenting Human Stem Cell Inventions 
 
So far it can be perceived that both health and technology laws are separate entities with very few things in 
common that could not actually allow any kind of research that pushes the stem cell and genetics envelope 
and here it is where the directive 98/44/EC of The European Parliament And Of The Council regarding the 
legal protection of biotechnological inventions which states that patent protection is necessary to encourage 
vital investment in the biotechnology industry. The law distinguishes between discoveries (i.e. materials that 
already exist and add to or extend scientific knowledge) which cannot be patented and inventions defined as 
covering gene sequences (ie the technical process to isolate or reproduce a natural element) which are 
patentable. Also the directive states that DNA or the genetic code of human beings cannot be patented but 
industrial applications or products involving DNA can be patented if they meet the criteria for ’invention’ 
which include novelty, innovation and industrial applicability. This means that a particular gene is not 
patentable but the process leading to its discovery and isolation can be.78 And the EUROSTEM which forms 
part of the European Union's Fifth Framework Programme on Quality of Life and Management of Living 
Resources. This project was concerned with the Ethics of Human Stem Cell Research and Therapy in 
Europe. Its main objectives, within a context of respect for fundamental human values, have been:  
• The creation of an ethical stem cell research structure in order to clarify policies, function of 
researchers, rights and ethical issues.  
• The evaluation of the legal EU framework (research & development of laws and regulations) 
• The identifications en crucial ethical concerns that could be brought up by the research in order to 
have an adequate approach to all involved actors such as the community, governments and industries.   
Both the directive 98/44/EC and the previous EUROSTEM system provide a somehow strong link that 
tackles in a community level most of the concerns regarding biotech and stem cell research from a legal and 
ethical point of view.  
On one hand the directive 98/44/EC (from now on biotech directive) obliges the Commission to report on the 
scope of patents on sequences of genes which have been isolated from the human body; and the patentability 
of human stem cells and cell lines obtained from them and on this tone the Commission  will continue to 
monitor the economic consequences of the differing legislative environments in Member States regarding 
patents on gene sequences and forbids any possibility to patent totipotent stem cells ( cell that has the 
capacity to form an entire organism; human development begins when a sperm fertilizes an egg and creates a 
 
78 European Public Health Alliance, 2005. Biotechnology in Europe. Brussels http://www.epha.org/a/1886 
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single totipotent cell79 meaning that are capable of developing into a human being) on grounds of human 
dignity. This resolution certainly is quite precise and necessary given the fact that it would be extremely 
controversial, unethical and even immoral to patent in the future a human being. 
But on the other hand it also recognises that given the great “divergence of laws and laws among Member 
States, the patentability of pluripotent stem cells (cells that can develop into other types of cells but not into a 
human being) cannot be solved and the Commission report considers that it is premature to come to a 
definitive conclusion on this issue” 80. This resolution once more shows the refusal of the commission to take 
a clear position on the patenting of human stem cells since it leaves the door open regarding the pluripotent 
stem cells manipulation. 
Summing up we can say that the biotech directive does not permit patents on cloning human beings, 
modifying the genetic identity of human beings and the use of human embryos for industrial and commercial 
purposes but leaves open the gap without giving any answer to the possibility of patenting specific human 
stem cells that later on could be converted into further developed organs. 
By now the only legislation that addresses the patentability of stem cells are national Member States 
legislations so this is a very sensitive and sensible area since the commission has managed not to state their 
position saying that it is quite premature to give a conclusion on this matter and by this ignoring the 
potentially lucrative and large market that stem cell therapy will represent in the near future. Nevertheless the 
European Parliament adopted a resolution on the trade in human egg cells (P6_TA(2005)0074).81
 
This resolution in its core states that the human body shall not be a source of financial gain given the fact that 
media reports at the end of December 2004 uncovered the existence of a clinic in Romania specialising in the 
donation of egg cells to European Union nationals, particularly UK citizens, in return for financial 
compensation. After this was disclosed the UK HFEA (the Human Fertilisation and Embryology Authority) 
sent a team to Romania to inspect rumours that involved possibly unlawful payments to donors but was 
incapable to find any evidence that Romanian donors were being paid more than justifiable expenses, but as a 
result of the above the Government from Romania closed the clinic and sent this case to the Prosecutor's 
Office given the fact that there is a clear possibility of serious effects on women's life and health since they 
 
79 MedicineNet.com, 2006. Definition of Totipotent. 
http://www.medterms.com/script/main/art.asp?articlekey=18261http://www.medterms.com/script/main/art.asp?articlekey=18261  
80 European Public Health Alliance, 2005. Biotechnology in Europe. Brussels http://www.epha.org/a/1886 
81European Parliament, 2005. European Parliament resolution on the trade in human egg cells. Planned egg cell trade. 
http://www.europarl.eu.int/omk/sipade3?PUBREF=-//EP//NONSGML+TA+P6-TA-2005-
0074+0+DOC+PDF+V0//EN&L=EN&LEVEL=4&NAV=S&LSTDOC=Y 
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could become suppliers of raw material82 and ultimately Article 12 of Directive 2004/23/EC  states that 
“This directive should not interfere with decisions made by Member States concerning the use or non-use of 
any specific type of human cells, including germ cells and embryonic stem cells. If, however, any particular 
use of such cells is authorised in a Member State, this directive will require the application of all provisions 
necessary to protect public health, given the specific risks of these cells based on the scientific knowledge 
and their particular nature, and guarantee respect for fundamental rights. Moreover, this directive should 
not interfere with provisions of Member States defining the legal term ‘person’ or ‘individual’”83 making it 
clear that payments or compensations for cell and tissue donations in Europe is not acceptable and that cells 
and tissues must not in any degree be subject to trade. 
In more recent events there is the case of Case of Evans V. The United Kingdom where Natallie Evans 
started In-Vitro Fertilisation treatment with her then partner Howard Johnston in 2001 but he withdrew 
consent for the embryos to be used after they split up84. Currently Mrs. Evans cannot produce more eggs to 
get pregnant and this is the only option for her to have a family of her own and having access to this frozen 
embryos is the only way for her to have a baby of her baby with her own DNA.  In spite the sympathy of the 
court towards her case the right to a family life - enshrined in article eight of the European Convention of 
Human Rights: “Everyone has the right to respect for his private and family life, his home and his 
correspondence. There shall be no interference by a public authority with the exercise of this right except 
such as is in accordance with the law and is necessary in a democratic society in the interests of national 
security, public safety or the economic well-being of the country, for the prevention of disorder or crime, for 
the protection of health or morals, or for the protection of the rights and freedoms of others85.”- could not 
override Mr Johnston's withdrawal of consent. 
Finally the court concludes by saying that “by applying the appropriate principles to the case the correct 
approach on their view would be as follows: the interests of the party who withdraws consent and wants to 
have the embryos destroyed should prevail (if domestic law so provides), unless the other party (a) has no 
other means to have a genetically-related child; and (b) has no children at all; and (c) does not intend to 
 
82 European Parliament resolution on the trade in human egg cells, 2005. Planned egg cell trade. 
http://www.europarl.eu.int/omk/sipade3?PUBREF=-//EP//NONSGML+TA+P6-TA-2005-
0074+0+DOC+PDF+V0//EN&L=EN&LEVEL=4&NAV=S&LSTDOC=Y  
83 The European Parliament and the Council of the European Union, 2004. Directive 2004/23/EC Of The European Parliament And 
Of The Council on setting standards of quality and safety for the donation, procurement, testing, processing, preservation, storage 
and distribution of human tissues and cells. Official Journal of the European Union http://europa.eu.int/eur-
lex/pri/en/oj/dat/2004/l_102/l_10220040407en00480058.pdf  
84 BBC News , 2006. Woman loses frozen embryos fight. http://news.bbc.co.uk/2/hi/health/4779876.stm  
85 Council of Europe, 1950. The European Convention on Human Rights http://www.hri.org/docs/ECHR50.html#C.Art8 
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have recourse to a surrogate mother in the process of implantation. The court thinks this approach would 
strike a fair balance between public and private interests, as well as between conflicting individual rights 
themselves. This test is neutral, because it can equally apply to female and male parties”. 86
Here we have a clear example of the determination of the court to follow the resolutions and directives that 
prohibit trade with cells or tissues in spite the fact that it’s a very politically influence resolution. 
 
d. Legal discrepancies between laws 
 
So far we have seen several examples of why it is important to have a common union law that address the 
human stem cell patents and in this final section we will further more with some recent cases of disparities 
between the biotech directive, patent law and local MS legislations. 
 
The first real controversy goes back to the proposal of the Biotech Directive when The Netherlands opposed 
the directive and challenged it in court case C-377/9887 saying that it was against Article 230 EC. The 
Netherlands was convinced that only patentable aspect should be the biotechnological process but not the 
products that could be derived from this process. (They are against patenting any form of vegetable, animal 
or human life as well as biological material). 
The Court also took the view that the international obligations of the Member States do not preclude the 
patentability of biotechnological inventions. In the view of the Court, neither the Agreement on Trade-
Related Aspects of Intellectual Property Rights (TRIPs), nor the Agreement on Technical Barriers to Trade 
(TBT) nor the Rio Convention on Biological Diversity, prevent the States party to those international 
agreements from coordinating their practices in this field by means of a Community directive. Finally the 
directive is very precise by saying “that all processes the use of which offends against human dignity must be 
excluded from patentability, that is to say in particular processes for cloning human beings, processes for 
modifying the germ line genetic identity of human beings and uses of human embryos for industrial or 
commercial purposes.88” 
 
 
86 European Court of Human Rights, 2006. Case of Evans V. The United Kingdom 
http://news.bbc.co.uk/1/shared/bsp/hi/pdfs/07_03_06_echr.pdf 
87 Judgment of the Court of 9 October 2001Kingdom of the Netherlands v European Parliament and Council of the European 
Union 
http://www.google.co.uk/url?sa=t&ct=res&cd=1&url=http%3A%2F%2Feuropa.eu.int%2Fsmartapi%2Fcgi%2Fsga_doc%3Fsmart
api!celexplus!prod!CELEXnumdoc%26lg%3Den%26numdoc%3D61998J0377&ei=ahNaRPe0OomiiAKB1cmOBA&sig2=ykp95
PR39XwHnb4lu41D9Q 
88 European Commission Press and Information Division, 2001. Press Release No 48/01, 2001.  
http://europa.eu.int/cj/en/actu/communiques/cp01/aff/cp0148en.htm 
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As an outcome of this legal process the Netherlands was forced to accept the directive but it certainly raised 
new points of discrepancy or contradictions given some terms as ordre public or morality (which were not 
very clear). It is also important to mention that as supporters of the Netherlands were Italy and Norway. 
 
After this attempt to discredit the biotech directive came a very important controversy with one of the most 
controversial stem cell patent which is the so-called The Edinburgh patent (No. 0695351)89, owned by the 
University of Edinburgh. The patent which was granted in late 1999 concerns a method of genetically 
modifying animal stem cells so as to give them a survival advantage over unwanted differentiated cells. 
“Biotechnology researchers face the problem that stem cells may grow more slowly than other cells and thus 
be crowded out. The method described in the Edinburgh patent solves this problem by making it easier to 
culture and isolate desired stem cells.”90
 
After examining the application and granting the patent the EPO failed to insist on limiting the term 
"animal", which can be interpreted as extending to humans. The first protests rose against this patente by 
February 2000 and the next month oppositions were filed mainly by Germany and The Netherlands which 
have strong ethical oppositions against this kind of patented invention, since it involves embryonic (human 
stem cells) and its modifications. Finally the patent was upheld and modified to define the term “animal” and 
to prevent processes for cloning human beings, the genetic identity germ line (in particular the human one), 
the use of human embryos for any industrial or commercial purpose, also the genetically modifications of 
animals or plants without having a clear and “substantial” medical benefit.91 The University claimed that 
they never had the intension of cloning human beings. Here it is interesting to see how specially these two 
countries who have national restrictive policies regarding stem cell research immediately opposed to this 
patent (which is not common when a MS oppose a patent granted by the EPO) granted to the UK, a country 
with a very permissive R&D stem cell policy.92
 
 
89 European Patent Office, 2002. "Edinburgh" patent limited after European Patent Office opposition hearing  
http://www.european-patent-office.org/news/pressrel/2002_07_24_e.htm 
90 European Patent Office, 2002. Background information on the "Edinburgh" patent, Pg. 1 
 http://www.european-patent-office.org/news/pressrel/pdf/backgr_3.pdf 
91 R.G.C. Jenkins & Co, 2006. Amendment to Exclude Embryonic Stem Cells http://www.jenkins-
ip.com/pi_news/autumn2002/stem_cells.htm 
92 after Germany and the Netherlands initially apposed the patent the Italian government joined the opposition 
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We can also find discrepancies when The European Parliament expressed concern about the grant of 
European patent EP 1257168 B193 (see annex e.) since according to them it constitutes an infringement of the 
Directive that protects biotechnological inventions (98/44/EC). The MEPs  (Member of the European 
Parliament) argues that in such patent is also included the possibility of patentability of “non- patentable 
human germ cells”. That is why the MEP are disputing this patent by an official opposition before the EPO. 
Certainly the above must be taken into consideration by the EPO in the future to avoid having such problems 
regarding patents of stem cell related products or processes in spite the fact that this organization has been 
very meticulous about granting such patents in the past.. After the “Edinburgh patent” case (previously 
discussed), the EPO has stop granting patents for this kind of inventions. “Moreover, it has raised objections 
to the patentability of inventions pertaining to human embryonic stem cells in a number of applications that 
have been examined so far”.94 Once again we can see how two European institutions disagree having no real 
legal base to debate given the fact that the biotech directive doesn’t tackle such inventions and the refusal of 
the Commission to give their opinion on the matter. 
 
e. Towards the commercialisation of human stem cells 
 
By now we had learned that there are basically two forms of stem cells, adult and embryonic, and even the 
simple research and investigation of the later ones are causing a lot of controversy not only from a legal but 
from ethical and moral points of view. The previous discussion about the legal discrepancies and the 
problems raised by patents on this field are no soon to be over but certainly they are looking forward to pave 
the way towards a future commercialisation of human stem cells. 
 
Within the European Union the only country that has the most advanced, clear and precise legislation 
regarding stem cells is the United Kingdom, this giving it a privileged position not only within Europe but in 
a global scope and they are determined to take advantage and attain commercial value from this 
advantageous situation. 
 
The possible commercial opportunities from the stem cell sector can be divided into groups mentioned below 
from short term to long term prospect: 
 
93 European Patent Office, 2005. Method Of Cryopreserving Selected Sperm Cells 
http://v3.espacenet.com/textdes?DB=EPODOC&IDX=EP1257168&F=0&QPN=EP1257168&RPN=EP1257168&DOC=cca34af1
985009c5833bf8b78038dfaf56 
94 European Patent Office, 2005. The EPO follows the EU's Directive on biotechnology patents. 
 http://www.european-patent-office.org/news/pressrel/2005_10_27_e.htm 
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• Research applications:   differentiation of stem cell generated lines in the drug in the pharmaceutical 
industry to discover new drugs. (short term) 
• Enabling technologies: creation of cell banks, research tools, and technology for clinical production 
(medium term) 
• Therapeutics: one of the most promising (and controversial) aspects of stem cells which would enable 
the creation of new organs and tissues, the treatment of degenerative diseases (long term due to safety, 
clinical and regulatory issues)95 
 
Currently within Europe the only country that allows embryonic stem cell research is the UK96 thanks to The 
Human Fertilisation and Embryonic Act that establishes that embryonic stem cell research can be executed 
for research in infertility cases, gene abnormality, and for the development of treatments for serious genetic 
diseases. 97 It is important to mention that given the freedom of this Act the UK parliament was forced to 
create the Human Reproductive Cloning Bill that specifically among other things prohibits the implantation 
in a woman a human embryo that was created by other means other than fertilisation.98
 
The European Community is quite behind from taking action and tackling by harmonising Community Law 
giving guidelines towards the future of the commercialisation of European stem cell inventions. This is more 
than evident since the Commission hasn’t been able to take a stand about the patenting of stem cells (as 
discussed previously) and moreover the Commission has not even approached the topic of commercialisation 
of human stem cells, thus allowing for member states to have unequal development opportunities. 
 
The future commercialisation of stem cells (specifically embryonic ones) is far from becoming a reality and 
it certainly tackles with many different and diverse issues that most been foreseen and deal with right now 
and not to wait until its to late and the European stem cell national innovation systems have a clear and huge 
disparity (which is quite unequal by now). European law makers must make up their minds and tackle this 
issue given the fact that the stem cell industry has a huge growth potential and promises to change the way 
we humans live (specially the stem cell therapies). 
 
95 Perrin Nicola, 2005. The Global Commercialisation of UK Stem Cell Research. UK Trade and Investment. 
http://www.fco.gov.uk/Files/kfile/UKTIStemCellsReportAugust2005,0.pdf 
96 Ruling out Belgium since their research and financial scope is very small and relies a lot on other countries research. 
97 House of Commons, 1990. Human Fertilisation and Embryology Act. 
http://www.opsi.gov.uk/acts/acts1990/Ukpga_19900037_en_1.htm 
98 House of Commons, 2001. The Human Reproductive Cloning Bill. 
http://www.parliament.uk/commons/lib/research/rp2001/rp01-104.pdf  
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7. Conclusion 
 
It is clear by now that the national innovation systems on human stem cells through all Member States are 
very different and variable depending on their inherent competitive advantages but also on their national 
legislations. There is a lack of a precise patent law that tackles specifically the patentability of human stem 
cells in the EU fact that puts the Union in an unfavourable position from other regions of the world.  
 
Trying to extend the common patent law into human stem cells patents has clearly failed and has raised many 
legal and moral questions that had challenged certain decisions. That is why it is important to acknowledge 
the particularities of this kind of innovations in order to create a specific patent law system that deals with 
specific criteria which are inherent from such delicate processes.  
 
The European Commission should also take a more decisive roll in order to answer “the question” regarding 
human stem cells patents which since 1998 has refused to do; this would create a more balanced legal setting 
for all MS and would increase competitiveness in the European biotechnology sector.  
 
At the same time Member States must not only recognise the tremendous potential and importance of this 
industry but also create the right incentives and appropriate funding to increase their national stem cell 
innovation systems not only focusing on importing technology from third countries but creating them and 
empowering their scientists, universities and firms with the suitable linkages to promote long term 
sustainable growth. 
 
There is no better way to describe what challenges and opportunities this topic brings that what Dartmouth 
ethics Professor Ronald Green discussed as the promise and pitfalls of stem cell research: “There are two 
main ethical issues facing stem cell research around the world today. The upfront issue, of course, concerns 
the state and status of the human embryo and whether it's permissible to destroy human embryos in order to 
develop stem cell lines. Down the line, we're going to have a very serious set of issues around actually using 
them in human beings for transplant and therapeutic purposes. How safe are they? Will they become 
cancerous once they are implanted in an individual, and so on? What is the long-term effect of transplanting 
foreign material or even one's own embryonic type material into one's body? 
 63 
                                                
Therapeutic cloning is one of the most promising approaches in regenerative medicine. First of all because it 
permits us to produce stem cells that match your own body type. This is not an allotransplant of foreign 
material. It's your own cells brought back to their embryonic status. 
Beyond that therapeutic cloning is very promising in teaching us how to reprogram cells from the start. The 
day will come--probably not in my lifetime, but beyond that--when we will be able to take a cell from a 
person's body and reprogram that cell back to its juvenile form. So literally give people wholly new blood 
systems. And the way to get there is through understanding how the egg reprograms the nuclear DNA, which 
occurs in therapeutic cloning. But then taking that learning and applying it to cell technologies generally. 
I don't want to be uncharitable, but the current administration's approach to biotechnology by and large 
strikes me as disastrous. The government has repeatedly threatened punitive legislation to shut down this 
area. And most unfortunately, private venture capital that could support independent firms going into the 
area has dried up. The consequence is now that it's countries like Korea or China, which are actively funding 
this research from their governments, that are moving ahead in this area. 
I think that by the end of the century medicine, as we know it, is going to be profoundly transformed. People 
who are in serious accidents will have new skin and bone from their own DNA available to them. Aging will 
not be stopped. We will still age. But the profound conditions of aging that limit people's independence and 
mobility will be addressed. New organs for people. I really see a vision of a medicine that provides people 
health from birth through good old age is what we're dealing with here.”99
 
This topic is quite new and fascinating and somehow unexplored since results are going to be seen at least in 
a couple of decades that is why still there is time to modify and to tackle in a proactive way all issues 
surrounding the human stem cell research European innovation system since now the foundations are being 
built for what could be a very promising future for the Union, Member States, policy makers, firms and 
ultimately to human beings just like me or you. 
 
 
 
99 Green Ronald, 2005. The Ethics of Stem Cells (interview). Trustees of Dartmouth College 
http://www.dartmouth.edu/~news/releases/2005/11/30a.html 
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9. Annexe 
a. Differentiation of cells 
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b. Map of Countries with permissive policy of embryonic stem cell research 
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c. Article 6 of the Amsterdam Treaty  
"1.The Union is founded on the principles of liberty, democracy, respect for human rights and fundamental 
freedoms, and the rule of law, principles which are common to the Member States. 
2. The Union shall respect fundamental rights, as guaranteed by the European Convention for the Protection 
of Human Rights and Fundamental Freedoms signed in Rome on 4 November 1950 and as they result from 
the constitutional traditions common to the Member States, as general principles of Community law”102
 
d. Example of a US patent on human embryonic stem cells 
 
“One example is the US patent awarded to the Wisconsin Alumni Research Foundation (WARF), for human 
pluripotent stem cells derived from spare embryos created for infertility treatment. This broad patent covers 
both James Thomson’s method of isolating human embryonic stem cells (ESC) and the five undifferentiated 
stem cell lines derived. That patent gives WARF control over who may work with its five stem cell lines and 
for what purpose. WARF decided to provide access against a nominal fee to academic researchers and access 
against a negotiable fee to other scientists. In return for its funding of James Thomson’s research, the for-
profit Geron Corporation was granted a licence agreement by WARF. Geron holds exclusive rights to 
develop the stem cell lines isolated at the University of Wisconsin into three specific differentiated stem cell 
lines for commercial purposes.” 103
 
102 Treaty of Amsterdam, 1997. http://www.eurotreaties.com/amsterdamtext.html 
103 Nielsen Linda & Whittaker Peter, 2002. Ethical Aspects of Patenting Inventions Involving Human Stem Cells. Opinion of the 
European Group on Ethics in Science and New Technologies to the European Commission. Brussels.  
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e. Method of Cryopreserving Selected Sperm Cells 
 
“The present invention provides a method of cryopreserving sperm that have been selected for a specific 
characteristic. In a preferred embodiment, the method is employed to freeze sex-selected sperm. Although the 
cryopreservation method of the invention can be used to freeze sperm selected by any number of selection 
methods, selection using flow cytometry is preferred. The present invention also provides a frozen sperm 
sample that has been selected for a particular characteristic, such as sex-type. In preferred embodiments, the 
frozen sperm sample includes mammalian sperm, such as, for example, human, bovine, equine, porcine, 
ovine, elk, or bison sperm. The frozen selected sperm sample can be used in a variety of applications. In 
particular, the sample can be thawed and used for fertilization. Accordingly, the invention also includes a 
method of using the frozen selected sperm sample for artificial insemination or in vitro fertilization.” 104
 
 
 
 
 
 
 
 
 
 
 
 
104 European Patent Office, 2005. Method of Cryopreserving Selected Sperm Cells Abstract 
http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=EP1257168&F=0&QPN=EP1257168&RPN=EP1257168&DOC=cca34af
1985009c5833bf8b78038dfaf56 
